Oligonucleotide Therapeutics and Delivery : Pharmaceuticals : UK

<!DOCTYPE html > <html xmlns="http://www.w3.org/1999/xhtml"> <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="SKYPE_TOOLBAR" content="SKYPE_TOOLBAR_PARSER_COMPATIBLE" /><meta name="viewport" content="width=device-width, initial-scale=1" />  <script src="https://cdn-ukwest.onetrust.com/consent/2f42c8dd-6f0d-43ef-8823-35fceb025e84/otSDKStub.js" type="text/javascript" charset="UTF-8" data-domain-script="2f42c8dd-6f0d-43ef-8823-35fceb025e84" ></script> <script type="text/javascript"> function OptanonWrapper() { } </script>   <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-T3QT4FB');</script>   <script type="text/javascript" src="/_scripts/jquery.min.js"></script> <script type="text/javascript" src="/_scripts/bootstrap.min.js"></script> <script type="text/javascript" src="/_scripts/carouselTicker.min.js"></script> <script type="text/javascript" src="/_scripts/magnific-popup.js"></script> <script type="text/javascript" src="/_scripts/owl.carousel.min.js"></script> <script type="text/javascript" src="/_scripts/jquery.sidr.min.js"></script> <script type="text/javascript" src="/_scripts/jquery.validate.min.js"></script> <script type="text/javascript" src="/_scripts/additional-methods.min.js"></script> <script type="text/javascript" src="/_scripts/imagesloaded.pkgd.min.js"></script> <script type="text/javascript" src="/_scripts/popups/login.js?v=7"></script> <script type="text/javascript" src="/_scripts/popups/signup.js"></script> <script type="text/javascript" src="/_scripts/popups/speak.js"></script> <script type="text/javascript" src="/_scripts/popups/attend.js?v=1"></script> <script type="text/javascript" src="/_scripts/popups/sponsor.js"></script> <script type="text/javascript" src="/_scripts/popups/contact.js"></script> <script type="text/javascript" src="/_scripts/popups/gdpr.js?v=1"></script> <script type="text/javascript" src="/_scripts/popups/misc.js?v=4"></script> <script type="text/javascript" src="/_scripts/popups/downbroch.js?v=1"></script> <script type="text/javascript" src="/_scripts/new/ticker.js"></script> <script type="text/javascript" src="/_scripts/new/sliders.js?v=1"></script>  <script src="https://paypage-cdn.adflex.co.uk/MerchantLibrary/lib.min.js" type="text/javascript"></script> <script type="text/javascript" src="/_scripts/new/checkout.js?v=3"></script> <link href="/_styles/bootstrap.min.css" type="text/css" rel="stylesheet" /><link href="/_styles/jquery.sidr.dark.css" type="text/css" rel="stylesheet" /><link href="/_styles/magnific-popup.css" type="text/css" rel="stylesheet" /><link href="/_styles/owl.carousel.css" type="text/css" rel="stylesheet" /><link href="/_styles/style.css?v=6" type="text/css" rel="stylesheet" /> <script type="text/javascript" src="/_scripts/jquery.easing.js"></script> <script> $(document).ready(function () { $('.open-popup-link').magnificPopup({ type: 'inline', midClick: true // allow opening popup on middle mouse click. Always set it to true if you don't provide alternative source. }); }); </script> <title> Oligonucleotide Therapeutics and Delivery : Pharmaceuticals : UK </title> <link rel="canonical" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery" /> <script type="text/javascript"> $(window).scroll(function () { if ($(window).width() > 739) { var scroll = $(window).scrollTop(); if (scroll >= 600) { $(".mid_tab_banner").addClass("fixed2"); $(".mid_tab_sec").addClass("fixed2"); $(".daylist").addClass("fixed2"); } else { $(".mid_tab_banner").removeClass("fixed2"); $(".mid_tab_sec").removeClass("fixed2"); $(".daylist").removeClass("fixed2"); } } else { $(".mid_tab_banner").removeClass("fixed2"); $(".mid_tab_sec").removeClass("fixed2"); $(".daylist").removeClass("fixed2"); } }); function scrollToPosition(targetPos) { if (document.readyState === 'complete') { $('html, body').animate({ scrollTop: targetPos }, 100); } else { $(document).ready(function () { $('html, body').animate({ scrollTop: targetPos }, 100); }); } } $(document).ready(function () { var url = document.location.toString(); if (url.match('#')) { if (url.slice(-1) == "_") { url = url.substr(0, url.length - 1); } $('.nav-tabs a[href=#' + url.split('#')[1] + ']').tab('show'); } $('.nav-tabs a').on('shown.bs.tab', function (e) { window.location.hash = e.target.hash; window.scrollTo(0, 250); }) $('#DDNavigation li a,#btnDownloadCentre').click(function (e) { $('.nav-tabs a[href=' + $(this).attr('href') + ']').tab('show'); }) // Optimalisation: Store the references outside the event handler: var $window = $(window); function checkWidth() { var windowsize = $window.width(); if (url.match('#')) { if (url.split('#')[1] == "eventDetails") { if ( $(window).width() < 480) { window.scrollTo(0, 230); } } } } // Execute on load checkWidth(); // Bind event listener $(window).resize(checkWidth); }); $(window).ready(function () { $("#whySponsor-sponsor-overview-slider").owlCarousel({ items: 4, autoPlay: 3000, //Set AutoPlay to 3 seconds navSpeed: 600, navigation: true, navigationText: ["<", ">"], slideSpeed: 600, loop: true, center: true }); }); /* $(window).load(function () { var gdpr = getCookie("GDPRConsent"); $('#pop-GDPRConsent #GDPRConsent_eventid').text('6017') if (gdpr == "") { $.magnificPopup.open({ items: { src: '#pop-GDPRConsent' }, type: 'inline' }); } }); */ </script> <style> .columntext ul, .latestcontent ul { padding-left: 40px } .columntext li, .latestcontent li { list-style-type: disc; } </style> <meta property="og:title" content="Oligonucleotide Therapeutics and Delivery" /><meta property="og:image" content="https://www.smgconferences.com/eventImages/6017_overview.png?width=1036", /><meta property="og:description" content="SAE Media Group's Oligonucleotide Therapeutics and Delivery conference 9th - 10th September 2023" /><meta property="og:url" content="https://www.smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery" /> <meta name="google-site-verification" content="QUxvzCpDXhln4QcLK-Z5Sp9QR04rGEFbCeiY9Jxm53k" /></head> <body>  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-T3QT4FB" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <form method="post" action="./oligonucleotide-discovery-delivery" id="aspnetForm" style="height: 0;"> <div class="aspNetHidden"> <input type="hidden" name="ctl00_ToolkitScriptManager1_HiddenField" id="ctl00_ToolkitScriptManager1_HiddenField" value="" /> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__LASTFOCUS" id="__LASTFOCUS" value="" /> <input type="hidden" name="__VIEWSTATE1" id="__VIEWSTATE1" value="c3goobgsgi5qhou41gstk3a0_54777d1a-83c9-4cbe-be17-e58fb02c2b95" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['aspnetForm']; if (!theForm) { theForm = document.aspnetForm; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="https://ajax.aspnetcdn.com/ajax/4.6/1/WebForms.js" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ window.WebForm_PostBackOptions||document.write('<script type="text/javascript" src="/WebResource.axd?d=oZImrG5UtwhGQ2EFd2xYVfXxME8uqAgUJjvfYmUDuLNuZbTVjhVuiMfiJ9L2oLoXQXiM0aUb0aQ56yEdstw_TqT6ocb3Qsv7nTfVmIYw0FU1&t=638628243619783110"><\/script>');//]]> </script> <script type="text/javascript"> //<![CDATA[ var __cultureInfo = {"name":"en-GB","numberFormat":{"CurrencyDecimalDigits":2,"CurrencyDecimalSeparator":".","IsReadOnly":true,"CurrencyGroupSizes":[3],"NumberGroupSizes":[3],"PercentGroupSizes":[3],"CurrencyGroupSeparator":",","CurrencySymbol":"£","NaNSymbol":"NaN","CurrencyNegativePattern":1,"NumberNegativePattern":1,"PercentPositivePattern":1,"PercentNegativePattern":1,"NegativeInfinitySymbol":"-∞","NegativeSign":"-","NumberDecimalDigits":2,"NumberDecimalSeparator":".","NumberGroupSeparator":",","CurrencyPositivePattern":0,"PositiveInfinitySymbol":"∞","PositiveSign":"+","PercentDecimalDigits":2,"PercentDecimalSeparator":".","PercentGroupSeparator":",","PercentSymbol":"%","PerMilleSymbol":"‰","NativeDigits":["0","1","2","3","4","5","6","7","8","9"],"DigitSubstitution":1},"dateTimeFormat":{"AMDesignator":"AM","Calendar":{"MinSupportedDateTime":"\/Date(-62135596800000)\/","MaxSupportedDateTime":"\/Date(253402300799999)\/","AlgorithmType":1,"CalendarType":1,"Eras":[1],"TwoDigitYearMax":2049,"IsReadOnly":true},"DateSeparator":"/","FirstDayOfWeek":1,"CalendarWeekRule":2,"FullDateTimePattern":"dd MMMM yyyy HH:mm:ss","LongDatePattern":"dd MMMM yyyy","LongTimePattern":"HH:mm:ss","MonthDayPattern":"d MMMM","PMDesignator":"PM","RFC1123Pattern":"ddd, dd MMM yyyy HH\u0027:\u0027mm\u0027:\u0027ss \u0027GMT\u0027","ShortDatePattern":"dd/MM/yyyy","ShortTimePattern":"HH:mm","SortableDateTimePattern":"yyyy\u0027-\u0027MM\u0027-\u0027dd\u0027T\u0027HH\u0027:\u0027mm\u0027:\u0027ss","TimeSeparator":":","UniversalSortableDateTimePattern":"yyyy\u0027-\u0027MM\u0027-\u0027dd HH\u0027:\u0027mm\u0027:\u0027ss\u0027Z\u0027","YearMonthPattern":"MMMM yyyy","AbbreviatedDayNames":["Sun","Mon","Tue","Wed","Thu","Fri","Sat"],"ShortestDayNames":["Su","Mo","Tu","We","Th","Fr","Sa"],"DayNames":["Sunday","Monday","Tuesday","Wednesday","Thursday","Friday","Saturday"],"AbbreviatedMonthNames":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec",""],"MonthNames":["January","February","March","April","May","June","July","August","September","October","November","December",""],"IsReadOnly":true,"NativeCalendarName":"Gregorian Calendar","AbbreviatedMonthGenitiveNames":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec",""],"MonthGenitiveNames":["January","February","March","April","May","June","July","August","September","October","November","December",""]},"eras":[1,"A.D.",null,0]};//]]> </script> <script src="/ScriptResource.axd?d=khkmPYFAOU7d2Y-bUMUyQ_brWr3NNRtCccpO71ys36owLUDyjmN-SUgq3YC5ElMr8VL49txeNotB2cH9ZQXaPn5KqrHItjWM70XjglIJfQejPOxqIz8jatHA2SZt1HsO0&t=ffffffffdd783992" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ (window.Sys && Sys._Application && Sys.Observer)||document.write('<script type="text/javascript" src="/ScriptResource.axd?d=khkmPYFAOU7d2Y-bUMUyQ_brWr3NNRtCccpO71ys36owLUDyjmN-SUgq3YC5ElMr8VL49txeNotB2cH9ZQXaPn5KqrHItjWM70XjglIJfQejPOxqIz8jatHA2SZt1HsO0&t=ffffffffdd783992"><\/script>');//]]> </script> <script src="/ScriptResource.axd?d=kCGEEOkTaMA-ETUe9XtyMaoP2f9Ve0AMk8cO2dpfug3HRbMvbEACk2_P9aOGvBv0-5-ShQ3syc3FIHySKPiyhVmCHTNUTm4cRXeD8-RXStw2-nLeedpIfZaC97ueSZmmzBedTYno2aQ9jgw7f0ltKw2&t=ffffffffdd783992" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ (window.Sys && Sys.WebForms)||document.write('<script type="text/javascript" src="/ScriptResource.axd?d=kCGEEOkTaMA-ETUe9XtyMaoP2f9Ve0AMk8cO2dpfug3HRbMvbEACk2_P9aOGvBv0-5-ShQ3syc3FIHySKPiyhVmCHTNUTm4cRXeD8-RXStw2-nLeedpIfZaC97ueSZmmzBedTYno2aQ9jgw7f0ltKw2&t=ffffffffdd783992"><\/script>');//]]> </script> <script src="/ScriptResource.axd?d=iNKIkAPGpECD5JwIGUPvkUgkJsz8UySman5MYqbNmRiA8Zj6ANbOurMTmC_jp0xY1naCVrdGRAmBloCMQMrCKPqemnV06ELvTJEq_j5MRjlqLfJn9w4rytsd28ggnF2l9H194rxUDDno1aLGK738eZHgOCn139B2utTwMArGzT41&t=ffffffffdd783992" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ (window.Sys && Sys.Services)||document.write('<script type="text/javascript" src="/ScriptResource.axd?d=iNKIkAPGpECD5JwIGUPvkUgkJsz8UySman5MYqbNmRiA8Zj6ANbOurMTmC_jp0xY1naCVrdGRAmBloCMQMrCKPqemnV06ELvTJEq_j5MRjlqLfJn9w4rytsd28ggnF2l9H194rxUDDno1aLGK738eZHgOCn139B2utTwMArGzT41&t=ffffffffdd783992"><\/script>');Sys.Services._AuthenticationService.DefaultWebServicePath = '../../../Authentication_JSON_AppService.axd'; var PageMethods = function() { PageMethods.initializeBase(this); this._timeout = 0; this._userContext = null; this._succeeded = null; this._failed = null; } PageMethods.prototype = { _get_path:function() { var p = this.get_path(); if (p) return p; else return PageMethods._staticInstance.get_path();}, InitSession:function(succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'InitSession',false,{},succeededCallback,failedCallback,userContext); }, GetFirstname:function(succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'GetFirstname',false,{},succeededCallback,failedCallback,userContext); }, GetDialingCode:function(intCountryID,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'GetDialingCode',false,{intCountryID:intCountryID},succeededCallback,failedCallback,userContext); }, RegisterAccount:function(Username,Password,OptOut,Title,Surname,Firstname,Organisation,JobTitle,Phone,uid,country,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'RegisterAccount',false,{Username:Username,Password:Password,OptOut:OptOut,Title:Title,Surname:Surname,Firstname:Firstname,Organisation:Organisation,JobTitle:JobTitle,Phone:Phone,uid:uid,country:country},succeededCallback,failedCallback,userContext); }, SaveBasket:function(basket,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SaveBasket',false,{basket:basket},succeededCallback,failedCallback,userContext); }, ResetAccountPassword:function(Username,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ResetAccountPassword',false,{Username:Username},succeededCallback,failedCallback,userContext); }, ChangePassword:function(OldPassword,NewPassword,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ChangePassword',false,{OldPassword:OldPassword,NewPassword:NewPassword},succeededCallback,failedCallback,userContext); }, BrochureDownloadSignup:function(intEventID,strFirstName,strLastName,strEmail,strCompanyName,strTelephoneNumber,blnReceiveInfo,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'BrochureDownloadSignup',false,{intEventID:intEventID,strFirstName:strFirstName,strLastName:strLastName,strEmail:strEmail,strCompanyName:strCompanyName,strTelephoneNumber:strTelephoneNumber,blnReceiveInfo:blnReceiveInfo},succeededCallback,failedCallback,userContext); }, BrochureDownload:function(eventId,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'BrochureDownload',false,{eventId:eventId},succeededCallback,failedCallback,userContext); }, ComplementaryContentDownload:function(eventId,complementaryContentId,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ComplementaryContentDownload',false,{eventId:eventId,complementaryContentId:complementaryContentId},succeededCallback,failedCallback,userContext); }, ConferencePresentationDownload:function(intDownloadTypeID,intDownloadID,intEventID,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ConferencePresentationDownload',false,{intDownloadTypeID:intDownloadTypeID,intDownloadID:intDownloadID,intEventID:intEventID},succeededCallback,failedCallback,userContext); }, ProgrammeNotification:function(EventID,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ProgrammeNotification',false,{EventID:EventID},succeededCallback,failedCallback,userContext); }, ComplementaryContentDownloadNotification:function(EventID,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ComplementaryContentDownloadNotification',false,{EventID:EventID},succeededCallback,failedCallback,userContext); }, SetPaymentMethod:function(strEncryptedString,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SetPaymentMethod',false,{strEncryptedString:strEncryptedString},succeededCallback,failedCallback,userContext); }, ApplyVoucherCode:function(strWebVoucherCode,strOrderRef,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ApplyVoucherCode',false,{strWebVoucherCode:strWebVoucherCode,strOrderRef:strOrderRef},succeededCallback,failedCallback,userContext); }, SubmitSpeakerRequest:function(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,topic,isReturning,heardAboutSmi,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitSpeakerRequest',false,{eventId:eventId,notListedAbove:notListedAbove,howCanWeHelp:howCanWeHelp,organisation:organisation,website:website,title:title,firstName:firstName,surname:surname,email:email,phone:phone,add:add,topic:topic,isReturning:isReturning,heardAboutSmi:heardAboutSmi},succeededCallback,failedCallback,userContext); }, SubmitAttendRequest:function(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,isReturning,heardAboutSmi,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitAttendRequest',false,{eventId:eventId,notListedAbove:notListedAbove,howCanWeHelp:howCanWeHelp,organisation:organisation,website:website,title:title,firstName:firstName,surname:surname,email:email,phone:phone,add:add,isReturning:isReturning,heardAboutSmi:heardAboutSmi},succeededCallback,failedCallback,userContext); }, SubmitSponsorRequest:function(eventId,notListedAbove,isSponsorLead,isSponsorSpeaking,isSponsorExhibit,isSponsorNetworking,isSponsorCoffeeBreak,isSponsorLunch,isSponsorBranding,isSponsorLanyards,organisation,jobtitle,website,title,firstName,surname,email,phone,add,sponsorshipGoals,isReturning,heardAboutSmi,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitSponsorRequest',false,{eventId:eventId,notListedAbove:notListedAbove,isSponsorLead:isSponsorLead,isSponsorSpeaking:isSponsorSpeaking,isSponsorExhibit:isSponsorExhibit,isSponsorNetworking:isSponsorNetworking,isSponsorCoffeeBreak:isSponsorCoffeeBreak,isSponsorLunch:isSponsorLunch,isSponsorBranding:isSponsorBranding,isSponsorLanyards:isSponsorLanyards,organisation:organisation,jobtitle:jobtitle,website:website,title:title,firstName:firstName,surname:surname,email:email,phone:phone,add:add,sponsorshipGoals:sponsorshipGoals,isReturning:isReturning,heardAboutSmi:heardAboutSmi},succeededCallback,failedCallback,userContext); }, SubmitKeepUpToDateRequest:function(firstName,surname,email,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitKeepUpToDateRequest',false,{firstName:firstName,surname:surname,email:email},succeededCallback,failedCallback,userContext); }, SubmitGDPRConsentRequest:function(eventId,email,giveConsent,name,phone,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitGDPRConsentRequest',false,{eventId:eventId,email:email,giveConsent:giveConsent,name:name,phone:phone},succeededCallback,failedCallback,userContext); }, SubmitGeneralRequest:function(name,jobTitle,org,phone,email,enquiry,enquiryType,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitGeneralRequest',false,{name:name,jobTitle:jobTitle,org:org,phone:phone,email:email,enquiry:enquiry,enquiryType:enquiryType},succeededCallback,failedCallback,userContext); }, AuthoriseToken:function(strToken,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'AuthoriseToken',false,{strToken:strToken},succeededCallback,failedCallback,userContext); }} PageMethods.registerClass('PageMethods',Sys.Net.WebServiceProxy); PageMethods._staticInstance = new PageMethods(); PageMethods.set_path = function(value) { PageMethods._staticInstance.set_path(value); } PageMethods.get_path = function() { return PageMethods._staticInstance.get_path(); } PageMethods.set_timeout = function(value) { PageMethods._staticInstance.set_timeout(value); } PageMethods.get_timeout = function() { return PageMethods._staticInstance.get_timeout(); } PageMethods.set_defaultUserContext = function(value) { PageMethods._staticInstance.set_defaultUserContext(value); } PageMethods.get_defaultUserContext = function() { return PageMethods._staticInstance.get_defaultUserContext(); } PageMethods.set_defaultSucceededCallback = function(value) { PageMethods._staticInstance.set_defaultSucceededCallback(value); } PageMethods.get_defaultSucceededCallback = function() { return PageMethods._staticInstance.get_defaultSucceededCallback(); } PageMethods.set_defaultFailedCallback = function(value) { PageMethods._staticInstance.set_defaultFailedCallback(value); } PageMethods.get_defaultFailedCallback = function() { return PageMethods._staticInstance.get_defaultFailedCallback(); } PageMethods.set_enableJsonp = function(value) { PageMethods._staticInstance.set_enableJsonp(value); } PageMethods.get_enableJsonp = function() { return PageMethods._staticInstance.get_enableJsonp(); } PageMethods.set_jsonpCallbackParameter = function(value) { PageMethods._staticInstance.set_jsonpCallbackParameter(value); } PageMethods.get_jsonpCallbackParameter = function() { return PageMethods._staticInstance.get_jsonpCallbackParameter(); } PageMethods.set_path("oligonucleotide-discovery-delivery"); PageMethods.InitSession= function(onSuccess,onFailed,userContext) {PageMethods._staticInstance.InitSession(onSuccess,onFailed,userContext); } PageMethods.GetFirstname= function(onSuccess,onFailed,userContext) {PageMethods._staticInstance.GetFirstname(onSuccess,onFailed,userContext); } PageMethods.GetDialingCode= function(intCountryID,onSuccess,onFailed,userContext) {PageMethods._staticInstance.GetDialingCode(intCountryID,onSuccess,onFailed,userContext); } PageMethods.RegisterAccount= function(Username,Password,OptOut,Title,Surname,Firstname,Organisation,JobTitle,Phone,uid,country,onSuccess,onFailed,userContext) {PageMethods._staticInstance.RegisterAccount(Username,Password,OptOut,Title,Surname,Firstname,Organisation,JobTitle,Phone,uid,country,onSuccess,onFailed,userContext); } PageMethods.SaveBasket= function(basket,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SaveBasket(basket,onSuccess,onFailed,userContext); } PageMethods.ResetAccountPassword= function(Username,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ResetAccountPassword(Username,onSuccess,onFailed,userContext); } PageMethods.ChangePassword= function(OldPassword,NewPassword,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ChangePassword(OldPassword,NewPassword,onSuccess,onFailed,userContext); } PageMethods.BrochureDownloadSignup= function(intEventID,strFirstName,strLastName,strEmail,strCompanyName,strTelephoneNumber,blnReceiveInfo,onSuccess,onFailed,userContext) {PageMethods._staticInstance.BrochureDownloadSignup(intEventID,strFirstName,strLastName,strEmail,strCompanyName,strTelephoneNumber,blnReceiveInfo,onSuccess,onFailed,userContext); } PageMethods.BrochureDownload= function(eventId,onSuccess,onFailed,userContext) {PageMethods._staticInstance.BrochureDownload(eventId,onSuccess,onFailed,userContext); } PageMethods.ComplementaryContentDownload= function(eventId,complementaryContentId,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ComplementaryContentDownload(eventId,complementaryContentId,onSuccess,onFailed,userContext); } PageMethods.ConferencePresentationDownload= function(intDownloadTypeID,intDownloadID,intEventID,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ConferencePresentationDownload(intDownloadTypeID,intDownloadID,intEventID,onSuccess,onFailed,userContext); } PageMethods.ProgrammeNotification= function(EventID,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ProgrammeNotification(EventID,onSuccess,onFailed,userContext); } PageMethods.ComplementaryContentDownloadNotification= function(EventID,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ComplementaryContentDownloadNotification(EventID,onSuccess,onFailed,userContext); } PageMethods.SetPaymentMethod= function(strEncryptedString,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SetPaymentMethod(strEncryptedString,onSuccess,onFailed,userContext); } PageMethods.ApplyVoucherCode= function(strWebVoucherCode,strOrderRef,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ApplyVoucherCode(strWebVoucherCode,strOrderRef,onSuccess,onFailed,userContext); } PageMethods.SubmitSpeakerRequest= function(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,topic,isReturning,heardAboutSmi,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitSpeakerRequest(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,topic,isReturning,heardAboutSmi,onSuccess,onFailed,userContext); } PageMethods.SubmitAttendRequest= function(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,isReturning,heardAboutSmi,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitAttendRequest(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,isReturning,heardAboutSmi,onSuccess,onFailed,userContext); } PageMethods.SubmitSponsorRequest= function(eventId,notListedAbove,isSponsorLead,isSponsorSpeaking,isSponsorExhibit,isSponsorNetworking,isSponsorCoffeeBreak,isSponsorLunch,isSponsorBranding,isSponsorLanyards,organisation,jobtitle,website,title,firstName,surname,email,phone,add,sponsorshipGoals,isReturning,heardAboutSmi,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitSponsorRequest(eventId,notListedAbove,isSponsorLead,isSponsorSpeaking,isSponsorExhibit,isSponsorNetworking,isSponsorCoffeeBreak,isSponsorLunch,isSponsorBranding,isSponsorLanyards,organisation,jobtitle,website,title,firstName,surname,email,phone,add,sponsorshipGoals,isReturning,heardAboutSmi,onSuccess,onFailed,userContext); } PageMethods.SubmitKeepUpToDateRequest= function(firstName,surname,email,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitKeepUpToDateRequest(firstName,surname,email,onSuccess,onFailed,userContext); } PageMethods.SubmitGDPRConsentRequest= function(eventId,email,giveConsent,name,phone,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitGDPRConsentRequest(eventId,email,giveConsent,name,phone,onSuccess,onFailed,userContext); } PageMethods.SubmitGeneralRequest= function(name,jobTitle,org,phone,email,enquiry,enquiryType,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitGeneralRequest(name,jobTitle,org,phone,email,enquiry,enquiryType,onSuccess,onFailed,userContext); } PageMethods.AuthoriseToken= function(strToken,onSuccess,onFailed,userContext) {PageMethods._staticInstance.AuthoriseToken(strToken,onSuccess,onFailed,userContext); } var gtc = Sys.Net.WebServiceProxy._generateTypedConstructor; if (typeof(BasketItems) === 'undefined') { var BasketItems=gtc("BasketItems"); BasketItems.registerClass('BasketItems'); } //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAASvVXD1oYELeveMr0vHCmYPVi0kMSdTVUTG1voF0fiHcgpO3MFqIPLeyEaVVEMlwUvLjtxrnzfA0pRyMpqEAoQYN3BleO/Qw1FLF2nV9gHb2vx+Sb/n1nfsQ3vvU0HDxJ8=" /> </div> <script type="text/javascript"> //<![CDATA[ Sys.WebForms.PageRequestManager._initialize('ctl00$ToolkitScriptManager1', 'aspnetForm', [], [], [], 90, 'ctl00'); //]]> </script> <div class="container-fluid"> <header class="container"> <div class="col-md-3"> <a href="/Default.aspx"><img alt="Home" src="/_images/newsite/logo.png" /></a> </div> <div class="col-md-9"> <div class="participate"> <a href="/about-us/life-at-saemedia/">About Us</a> <a href="/privacy-legals/privacy-policy/">Privacy Policy</a> <a href="/privacy-legals/code-of-conduct/">Conduct</a> <a href="#pop-speak" class="open-popup-link">Speak</a> <a href="#pop-sponsor" class="open-popup-link">Sponsor</a> <a href="#pop-attend" class="open-popup-link">Attend</a> <span id="menu_signup_login" style=""> <a href="#pop-login" class="open-popup-link">Sign up / Login</a><a href="#pop-login" class="open-popup-link linkedin hidden" ></a> </span> <span id="menu_logout" style="display:none"> <a href="javascript:void(0)">Sign out</a> </span> </div> <div class="telmail text-right"> <span> <a href="#pop-contact" class="open-popup-link ">+44 (0)20 7827 6000</a> <a href="#pop-contact" class="open-popup-link">events@saemediagroup.com</a></span> </div> <div class="cart"> <a href="/checkout"><span><img src="/_images/newsite/shopping-cart-16.png" alt="cart" /> Basket Total: £0.00</span></a> </div> </div> </header> </div>  <nav class="navbar navbar-default container-fluid red main-nav"> <div class="container"> <div class="navbar-header"> <button type="button" class="navbar-toggle " id="simple-menu" data-target="#sidr"> <span class="sr-only">Toggle navigation</span> <span class="icon-bar"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> </button> </div>  <div id="sidr" class="hidden">  <div class="navbar-header pus-menu"> <button type="button" class="navbar-toggle" id="simple-menu2" data-target="#sidr" > <span class="sr-only">Toggle navigation</span> <span class="icon-bar"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> </button> </div> <ul> <li><a href="/Default.aspx">Home</a></li> <li> <a id="ctl00_midMenuMain_list_rSector_ctl00_sLnk" href="/defence/">Defence & Security</a> </li> <li> <a id="ctl00_midMenuMain_list_rSector_ctl01_sLnk" href="/utility/">Utilities</a> </li> <li> <a id="ctl00_midMenuMain_list_rSector_ctl02_sLnk" class="sectorselected" href="/pharmaceuticals/">Pharmaceuticals</a> </li>  <li> <a href="https://www.saemediagroup.com" target="_blank">Digital & Print Media</a> </li> <li><a href="/about-us/life-at-saemedia/">About Us</a></li> <li><a href="/privacy-legals/privacy-policy/">Privacy Policy</a></li> <li><a href="/privacy-legals/code-of-conduct/">Conduct</a></li> <li><a href="#pop-speak" class="open-popup-link">Speak</a></li> <li><a href="#pop-sponsor" class="open-popup-link">Sponsor</a></li> <li><a href="#pop-attend" class="open-popup-link">Attend</a></li> <li><a href="/about-us/help">Help</a></li> </ul> </div> <script> $(document).ready(function () { $('#simple-menu').sidr('open'); $('#simple-menu2').sidr('close'); $('#sidr').removeClass('hidden'); }); </script> <div class="collapse navbar-collapse" id="main-nav"> <ul class="nav navbar-nav"> <li><a href="/Default.aspx">Home</a></li> <li> <a id="ctl00_midMenuMain_navbar1_list_rSector_ctl00_sLnk" href="/defence/">Defence & Security</a> </li> <li> <a id="ctl00_midMenuMain_navbar1_list_rSector_ctl01_sLnk" href="/utility/">Utilities</a> </li> <li> <a id="ctl00_midMenuMain_navbar1_list_rSector_ctl02_sLnk" class="sectorselected" href="/pharmaceuticals/">Pharmaceuticals</a> </li>  <li> <a href="https://www.saemediagroup.com" target="_blank">Digital & Print Media</a> </li> </ul> </div> <div class="search" style="display:none;"> <input name="ctl00$midMenuMain$search1$TextBoxSearch" type="text" maxlength="32" onchange="javascript:setTimeout('__doPostBack(\'ctl00$midMenuMain$search1$TextBoxSearch\',\'\')', 0)" onkeypress="if (WebForm_TextBoxKeyHandler(event) == false) return false;" id="ctl00_midMenuMain_search1_TextBoxSearch" /> <a href="#pop-cpd" class="open-popup-link"><img src="/_images/newsite/cpd.png" alt="" class="cpdimg"/></a> </div> </div> </nav> <input type="hidden" name="ctl00$MainContent$eventID" id="ctl00_MainContent_eventID" value="6017" /> <input type="hidden" name="ctl00$MainContent$peventID" id="ctl00_MainContent_peventID" /> <div class="container-fluid darkgrey hidden"> <div class="container carouselTicker"> <ul class="newsticker"> </ul> </div> </div> <div class="image-bg-fluid-height banner" id="intro" style="background: url('https://smgconferences.com/_images/eventBanners/6017.png') no-repeat 0 0; background-size: cover; "> <div class="container" style="position:relative; min-height:inherit;"> <div class="dropdown" id="DDNavigation"> <button class="btn btn-default dropdown-toggle" type="button" id="dropdownMenu1" data-toggle="dropdown" aria-expanded="true"> Navigation <span class="caret"></span> </button> <ul class="dropdown-menu" role="menu" aria-labelledby="dropdownMenu1"> <li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_overview">Overview</a></li> <li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_programme">Agenda</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_speakers">Speakers</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_sponsors">Sponsors</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_partners">Partners</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_venue">Venue</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_downloads">Content</a></li> </ul> </div> <div class="banner-content"> <h1 style="color:#fff;">Oligonucleotide Therapeutics and Delivery</h1> <h3 class="pink-header" style="color:#fff;"> 9 September - 10 September 2024 <br /> London, United Kingdom<br /> </h3> <p style="color:#000;">DRIVING THE ADVANCEMENT OF OLIGONUCLEOTIDE DISCOVERY AND TARGET SPECIFICITY</p> <div class="col-xs-12 bottomAlignButtons"> <div class="col-sm-6" style="padding: 0;"> <ul class="button_list"> <li><a href="https://smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery/booknow" target="" class="button-blue">Buy Conference Papers</a></li> </ul>  </div>  </div> </div> </div> </div> <div class="mid_tab_sec mid_tab_sec_edit"> <div class="container"> <div class="row"> <div class="col-sm-12"> <div class="mid_tab_Inner"> <div class="mid_top"> <div class="mid_tab_banner /*image-bg-fluid-height banner*/" style="background: url('https://smgconferences.com/_images/eventBanners/6017.png?height=50&width=1140&mode=crop') no-repeat 0 0;"> <div style="font:700 20px/24px Montserrat; color:#fff; padding-left: 5px; padding-top: 4px;">Oligonucleotide Therapeutics and Delivery</div> <div style="font:500 16px/18px Montserrat; color:#fff; padding-left: 5px; ">9 September - 10 September 2024</div> </div> <ul class="nav nav-tabs mid_tab mid_tab_edit" role="tablist">  <li role="presentation"><a href="#tab_overview" aria-controls="tab_new1" role="tab" data-toggle="tab">Overview</a></li> <li id="ctl00_MainContent_liProgramme" role="presentation"><a href="#tab_programme" aria-controls="tab_programme" role="tab" data-toggle="tab">Agenda</a></li> <li id="ctl00_MainContent_liSpeakers" role="presentation"><a href="#tab_speakers" aria-controls="tab_speakers" role="tab" data-toggle="tab">Speakers</a></li> <li id="ctl00_MainContent_liSponsors" role="presentation"><a href="#tab_sponsors" aria-controls="tab_sponsors" role="tab" data-toggle="tab">Sponsors</a></li> <li id="ctl00_MainContent_liPartners" role="presentation"><a href="#tab_partners" aria-controls="tab_partners" role="tab" data-toggle="tab">Partners</a></li> <li id="ctl00_MainContent_liVenue" role="presentation"><a href="#tab_venue" aria-controls="tab_venue" role="tab" data-toggle="tab">Venue</a></li> <li id="ctl00_MainContent_liDownload" role="presentation"><a href="#tab_downloads" aria-controls="tab_downloads" role="tab" data-toggle="tab">Content</a></li> </ul> <div class="sponcer_event2 sponcer_event_edit" style="float:right"> <ul> <li><a href="https://smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery?o=db&dl=br&p1=6017">Download Brochure</a></li> <li><a href="https://smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery/booknow" target="" class="actv">Register To Attend</a></li> </ul> </div> </div> </div> </div> </div> </div> </div>  <div class="tab_main"> <div class="container"> <div class="row"> <div class="col-sm-12"> <div class="tab-content"> <div role="tabpanel" class="tab-pane active" id="tab_overview"> <div class="overview"> <div class="row"> <div class="col-md-6"> <div class="overview_pic"> <img id="ctl00_MainContent_ctl02_imgOverviewImage" src="/eventImages/6017_overview.png?width=1036" alt="Oligonucleotide Therapeutics and Delivery" /> </div> <div class="col-sm-12" style="margin-top:20px;"> <div class="sharethis "> <div class="share"> <p class="pink-header" style="text-align: left;">follow us</p> <a id="ctl00_MainContent_ctl02_hypLinkedIn" class="addthis_button_linkedin linkedin" href="https://www.linkedin.com/company/saemediagrouppharma/" target="_blank"> <img src="/_images/newsite/In-2C-48px-R.png" border="0" alt="Follow us on LinkedIn" /> </a> <a id="ctl00_MainContent_ctl02_hypTwitter" class="addthis_button_twitter twitter" href="https://x.com/saemgpharma" target="_blank"> <img src="/_images/newsite/x-logo-black.png" border="0" alt="Follow us on X" /> </a> </div> </div> </div> </div> <div class="col-md-6"> <div style="background-color: #fff;border: none;border-bottom: 1px solid #000;padding: 0;"> <h4 class="panel-title"> <a data-toggle="collapse" data-parent="#accordion" href="#collapseOne" aria-expanded="true" aria-controls="collapseOne">Conference Overview </a> </h4> </div> <div class="panel-body" id="divOverview"> <p> </p> <p>Step into the forefront of innovation at SAE's 4th annual <strong>Oligonucleotide Therapeutics and Delivery</strong> conference!</p> <p>Deep dive into the latest breakthroughs in oligonucleotide development, regulatory compliance, and CMC considerations. Discover cutting-edge strategies to elevate oligonucleotide discovery and precision targeting. Explore optimized delivery methodologies for oligonucleotide-based therapies, propelling the frontier of oligonucleotide drug development forward.</p> <p>Don't miss your chance to be part of this transformative event on 9 – 10 September.</p> <p>Join us and shape the future of therapeutic advancement!</p> <p><u><strong>Why should you attend?</strong></u></p> <ul> <li>Benchmark against leading big pharma case studies to advance your manufacturing and analytical strategies for advanced oligonucleotide synthesis</li> <li>Explore the potential of industry cross collaboration with insights from working groups, regulatory bodies and senior big pharma and biotech experts leading the way in driving advancements for genetic medicine</li> <li>Learn how AI is propelling drug discovery forward for sequence design and unlocking undruggable proteins and how this can translate to your pipelines</li> <li>Engage in the latest drug delivery technologies, optimising target specificity for RNA therapeutics and vaccines <br />  </li> </ul> <p> </p> </div> </div> </div> </div> <div id="speakers"> <h2>FEATURED SPEAKERS</h2> <div id="keynote-slider"> <div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/222879.png?width=250&height=250&bgcolor=white&scale=canvas" alt="David Tew" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">David Tew</a></h3> <div class="speaker-details">Senior Scientific Director, Enzyme Engineering and Biocatalysts (E2B), GSK</div> <div class="speaker-profile hidden"><p>David Tew is a Senior Scientific Director at GSK. David has 35 years of experience in the pharmaceutical industry including early drug discovery, mechanistic enzymology, assay development, reagent generation and the application of Synthetic Biology. Most recently David has been leading a project to apply Synthetic Biology to redesign the manufacture of therapeutic oligonucleotides. This has resulted in a platform approach to therapeutic oligonucleotide synthesis and manufacture that is both scalable and more sustainable than current approaches. <br /> In 2018 David was appointed as The Royal Society Entrepreneur in Residence at Bristol University working with BrisSynBio and the Bristol Biodesign Institute. David held this position until 2022.<br /> During the SARS-CoV-2 pandemic, David lead the innovation workstream for the Cambridge COVID-19 Testing Centre, a collaboration between AstraZeneca, GlaxoSmithKline and the University of Cambridge.<br />  </p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/222878.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Nagy Habib" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Nagy Habib</a></h3> <div class="speaker-details">Professor of Surgery, Imperial College London, Co-Founder, MiNA, Apterna and Dawn Therapeutics</div> <div class="speaker-profile hidden"><p>For over three decades Nagy has been at the forefront of clinical research and clinical practise in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene therapy delivery. He was the first in Europe to perform a clinical trial with the use of adult CD34+ stem cells in patients with liver failure and stroke.<br /> Nagy is a founder and was the Head of R&D of Mina therapeutics whilst at Mina he was driving the development of saRNA drug (a new class of medicines) which is currently being trialled in patients with liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, Clinical Trials.gov ID NCT02716012) and in a second trial in patients with solid tumours (TIMEPOINT study, ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan.<br /> He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Currently he is the CEO of Apterna Limited, a company focussed on novel oligonucleotide delivery and Dawn Therapeutics specialising in gene therapy. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018).<br /> Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.</p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/222880.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Peter Smith" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Peter Smith</a></h3> <div class="speaker-details">Director, New Modalities Chemistry, AstraZeneca</div> <div class="speaker-profile hidden"><p>Peter Smith is currently Director, New Modalities Chemistry within AstraZeneca’s Early Chemical Development group based in Macclesfield, UK. Peter has a background in synthetic organic chemistry (BSc Hons Glasgow, PhD Heriot-Watt, PDRA Sussex) and has worked at AstraZeneca for over 20 years in a variety of chemistry roles. During 2016, Peter took the position of early-phase Oligonucleotide chemistry lead, responsible for chemical development and drug substance manufacturing of AZ’s early-phase oligonucleotide clinical portfolio, and since then has progressed to his current role where he has accountability across the fields of oligonucleotides, peptides, ADC’s and ionizable lipids.</p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/222933.png?width=250&height=250&bgcolor=white&scale=canvas" alt="Samir Ounzain" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Samir Ounzain</a></h3> <div class="speaker-details">Senior Chief Executive Officer and Scientific Co-Founder, HAYA Therapeutics</div> <div class="speaker-profile hidden"><p>Samir Ounzain is a molecular biologist with over 15 years of experience exploring the dark matter of the genome and its roles in development and disease.<br /> Prior to founding HAYA Therapeutics, Samir was a Project Leader and Research Fellow at the Lausanne University Hospital (CHUV), where his research efforts directly led to the discovery of hundreds of novel heart-enriched lncRNAs, most notably the lncRNAs CARMEN, Meteor and Wisper.<br />  </p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/222882.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Thierry Dorval" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Thierry Dorval</a></h3> <div class="speaker-details">Head of Data Sciences & Data Management, Servier Pharmaceuticals</div> <div class="speaker-profile hidden"><p>Thierry Dorval received a B.S. degree in theoretical physic and obtained a Ph.D. in image processing and artificial intelligence at Pierre & Marie Curie University, Paris, France. He then joined the Institut Pasteur Korea in 2005 first as researcher in biological image analysis then as a group leader specialized in High Content Screening applied to cellular differentiation as well as toxicity prediction. In 2012 he joined AstraZeneca, UK, where he was leading the Image and Data Analytics team. His activities were about developing and advising on quantitative image and data analysis solutions in support of high content phenotypic screens. <br /> In 2015 he joined Servier, France, first as leader of the High Content Screening group within CentEX CPCB and then as Head of Data Science Lab, working on phenotypic approaches to improve drug discovery pipeline efficiency using high content and machine learning strategies.<br />  </p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/222885.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Thomas Thum" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Thomas Thum</a></h3> <div class="speaker-details">Founder, Chief Scientific Officer and Chief Medical Officer, Cardior Pharmaceuticals GmbH</div> <div class="speaker-profile hidden"><p>Prof. Dr. Dr. med. Thomas Thum, Founder, managing director and CSO/CMO of Cardior Pharmaceuticals GmbH, is a key opinion leader in cardiac diseases and the development of RNA-based therapeutics. He has received numerous awards for his work. Thomas is a member of the editorial boards of the world’s most prestigious journals for cardiovascular research and an executive member of national and international research committees in the cardiovascular field. Since 2009 Thomas is Director of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hanover Medical School (MHH) and visiting professor at the National Heart and Lung Institute at Imperial College London since 2013. From 2021 to 2023 he was Director of the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hanover, Germany. Thomas Thum has authored over 500 scientific publications in renowned and field-leading journals and has filed over 50 patents, with many of them licensed and some already under clinical development.</p></div></div></div> </div> <script> $(window).ready(function () { $("#keynote-slider").owlCarousel({ //autoPlay: 3000, //Set AutoPlay to 3 seconds slideSpeed: 600, pagination: false, navigation: true, navigationText: ["<", ">"], stopOnHover: true, items: 4, itemsDesktop: [1199, 3], itemsDesktopSmall: [979, 3], center: true, loop: true }); }); </script> <div class="row"> <div class="col-md-12 sponsors marg2"> <div class="buttons"> <a id="hlAll" href="#pop-speakers-all" class="open-popup-link button-white">view all speakers</a> </div> </div> </div> <div id="pop-speakers-all" class="white-popup mfp-hide"> <br> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Alessandro Bonetti</h3> Principal Scientist, R&D Biopharmaceuticals, AstraZeneca </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl01_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/silhouette_M.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Alessandro Bonetti" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Dr. Alessandro Bonetti obtained his Master degree in Medical Biotechnologies at the University of Naples in 2001 and moved to Helsinki for his PhD studies where he investigated the genetic prediposition to multiple sclerosis in Nordic populations. He then moved to RIKEN Yokohama to study the biological role of long non-coding. During that time he developed numerous technologies to identify the functional relevance of non-coding transcripts in physiological and pathological conditions. Subsequently he joined AstraZeneca to lead the transcriptomic studies in the Oligonucleotide platform. In October 2022 he was appointed Principal Scientist to lead the non-coding initiative in AZ.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Christoph Hein</h3> Division Director, Ultra- and Highprecision Technology, Fraunhofer IPK </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl02_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/225479.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Christoph Hein" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Dr. Christoph Hein is Director of the Ultra- and High-Precision Technology Division at the Fraunhofer IPK in Berlin. He studied biomedical engineering at the Technical University of Berlin and completed his doctorate in the field of micro-optical structures. At Fraunhofer IPK, he and his team are researching advanced technologies for the production, modification and transport of nanoparticles for applications in the field of oligonucleotide therapeutics and delivery.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Daniel Elbaum</h3> Chief Scientific Officer, QurAlis </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl03_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/222887.png?width=200&height=190&bgcolor=white&scale=canvas" alt="Daniel Elbaum" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Daniel (Dan) Elbaum, PhD, is a drug discovery and development leader with nearly three decades of experience. He thrives on making new discoveries and connections and has made significant contributions in the fields of oncology, inflammation, and orphan diseases. He has worked in large organizations including Pfizer and Amgen, as well as several start-up companies including Kinetix Pharmaceuticals and FoldRx Pharmaceuticals (acquired by Pfizer). He was senior director, chemistry and portfolio management, and co-head of the research and non-clinical development group at Retrophin. To keep abreast of cutting-edge research, he actively maintains close ties with the academic and start-up communities.<br /> <br /> Dan earned his PhD and undergraduate degrees in chemistry from Harvard University, and conducted postdoctoral research at the University of Pennsylvania. An inventor on more than 25 patents and an author on more than 15 peer-reviewed publications, Dan is a mentor in the Kindle Mentors Program at Boston University and a longstanding member of the American Chemical Society and the Association for the Advancement of Science.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">David Evans</h3> CSO, Sirnaomics, Inc </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl04_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/222949.png?width=200&height=190&bgcolor=white&scale=canvas" alt="David Evans" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>David M. Evans, Ph.D, Co-founder and CSO, Sirnaomics Inc. Gaithersburg, MD. Dr. Evans has over 25 years experience in drug target and small molecule discovery for oncology, infectious diseases and CNS therapeutics. He has been involved in the RNAi field since 2003. As Head of Drug Discovery for the Cancer Drug Development Lab for TGEN and as Sr. Director, RNAi Discovery and Therapeutic Services group, Dharmacon group, Thermo Fisher Scientific (TFS), he built HTS operations to identify targets that synergized with known oncology therapeutics. In 2008 Davidwas a cofounder of Sirnaomics and has led the R&D group with afocus on using siRNAs as therapeutics in their own right. Sirnaomics now has several candidates in clinical testing and a<br /> rich pipeline of preclinical products. David received his BSc(1983) and PhD (1987) from Imperial College, London and has published a number of peer reviewed papers and review articles.<br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">David Tew</h3> Senior Scientific Director, Enzyme Engineering and Biocatalysts (E2B), GSK </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl05_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/222879.png?width=200&height=190&bgcolor=white&scale=canvas" alt="David Tew" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>David Tew is a Senior Scientific Director at GSK. David has 35 years of experience in the pharmaceutical industry including early drug discovery, mechanistic enzymology, assay development, reagent generation and the application of Synthetic Biology. Most recently David has been leading a project to apply Synthetic Biology to redesign the manufacture of therapeutic oligonucleotides. This has resulted in a platform approach to therapeutic oligonucleotide synthesis and manufacture that is both scalable and more sustainable than current approaches. <br /> In 2018 David was appointed as The Royal Society Entrepreneur in Residence at Bristol University working with BrisSynBio and the Bristol Biodesign Institute. David held this position until 2022.<br /> During the SARS-CoV-2 pandemic, David lead the innovation workstream for the Cambridge COVID-19 Testing Centre, a collaboration between AstraZeneca, GlaxoSmithKline and the University of Cambridge.<br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Heinrich Haas</h3> Chief Technology Officer, NeoVac </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl06_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/silhouette_M.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Heinrich Haas" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Joanna Hemming Taylor</h3> Associate Principal Scientist, AstraZeneca </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl07_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/222962.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Joanna Hemming Taylor" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Joanna Hemming Taylor graduated with a MChem in Chemistry with industrial experience from the University of Manchester in 2009, followed by a PhD in biophysical and computational chemistry from University College London with an emphasis on characterisation of lipids and peptides at the air-liquid interface. In 2014 Joanna joined AstraZeneca and has worked as an analytical project lead on multiple early phase clinical projects, from small molecule therapeutics to larger synthetics such as peptides and drug-dendrimer conjugates. Most recently, Joanna has been responsible for leading the analytical development of siRNA projects within Early Chemical Development.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Marco Mina</h3> Director, Head of Comp Bio and Data Science, HAYA Therapeutics </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl08_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/225480.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Marco Mina" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Marco Mina is a computer scientist and computational biologist with 10+ years’ experience in Data Science, Bioinformatics and Computational Biology. After receiving his doctoral degree in Information Engineering from the University of Padova (Italy), Marco held a postdoctoral position in Cancer Genomics at the University of Lausanne, focusing on functional dependencies between cancer mutations and their therapeutic actionability. He later transitioned to industrial research at SOPHiA Genetics, leading a team focusing on variant annotation and pathogenicity prediction for the interpretation of patient molecular data. At HAYA Therapeutics, Marco is leading the Data Science and Computational Biology unit. His team focuses on multiple R&D aspects of the target discovery and drug discovery and nomination platforms. During his career, Marco published more than 20 articles (10+ as first co-author, > 7000 citations) in world-leading, peer-reviewed journals including Cell, Cancer Cell and Nature Genetics.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Nagy Habib</h3> Professor of Surgery, Imperial College London, Co-Founder, MiNA, Apterna and Dawn Therapeutics </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl09_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/222878.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Nagy Habib" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>For over three decades Nagy has been at the forefront of clinical research and clinical practise in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene therapy delivery. He was the first in Europe to perform a clinical trial with the use of adult CD34+ stem cells in patients with liver failure and stroke.<br /> Nagy is a founder and was the Head of R&D of Mina therapeutics whilst at Mina he was driving the development of saRNA drug (a new class of medicines) which is currently being trialled in patients with liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, Clinical Trials.gov ID NCT02716012) and in a second trial in patients with solid tumours (TIMEPOINT study, ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan.<br /> He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Currently he is the CEO of Apterna Limited, a company focussed on novel oligonucleotide delivery and Dawn Therapeutics specialising in gene therapy. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018).<br /> Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Peter Smith</h3> Director, New Modalities Chemistry, AstraZeneca </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl10_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/222880.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Peter Smith" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Peter Smith is currently Director, New Modalities Chemistry within AstraZeneca’s Early Chemical Development group based in Macclesfield, UK. Peter has a background in synthetic organic chemistry (BSc Hons Glasgow, PhD Heriot-Watt, PDRA Sussex) and has worked at AstraZeneca for over 20 years in a variety of chemistry roles. During 2016, Peter took the position of early-phase Oligonucleotide chemistry lead, responsible for chemical development and drug substance manufacturing of AZ’s early-phase oligonucleotide clinical portfolio, and since then has progressed to his current role where he has accountability across the fields of oligonucleotides, peptides, ADC’s and ionizable lipids.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Priya Karmali</h3> Chief Technology Officer, Capstan Therapeutics </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl11_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/222886.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Priya Karmali" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Priya Karmali, PhD. is Chief Technology Officer at Capstan Therapeutics and leads all aspects of technology development. Priya has over 20 years of experience in the field of lipid nanoparticle delivered nucleic acid therapeutics from discovery through development. Prior to Capstan, Priya served as Vice President of Technology Innovation and Development at Arcturus Therapeutics. Previously, Priya held positions of increasing responsibility at Regulus Therapeutics and Nitto. Priya has a PhD in Chemistry from Indian Institute of Chemical Technology (India) where her doctoral research was focused on development of novel liposomal nucleic acid delivery systems for use in non-viral gene therapy and DNA vaccination. She pursued her postdoctoral research at Sanford-Burnham-Preby’s-Medical Discovery Institute, La Jolla, CA focusing on developing targeted nanoparticles for drug delivery. Priya is an author and co-inventor on over 70 publications and patents in the field.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Rabia Khan</h3> Founder & CEO, Serna.bio </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl12_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/222881.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Rabia Khan" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Rabia Khan, PhD (Immuno Genetics, MBA) is the founder and CEO of Serna Bio, a YC-backed biotech building the world's first map of the druggable transcriptome. She is a member of the Board of Trustees for the UK Dementia Research Institute, and an advisor to No Label Ventures, a fund investing in immigrant founders in the UK and EU.</p> <p>Prior to founding Serna Bio, Rabia was Managing Director, Discovery Sciences at Sensyne Health plc (now - Arctoris Data) where she established the scientific strategy, built the data science and discovery teams by recruiting and leading a team of 50 machine learning and clinical researchers, delivering on a number of significant pharma partnerships including Bayer, BMS, Roche and Alexion.</p> <p>She also held senior roles at BenevolentAI and Meta (acquired by Chan Zuckerberg BioHub). At Meta (previously Sciencescape), she was pivotal in the partnership with the Intelligence Advanced Research Projects Activity (IARPA) to acquire horizon-scanning technology that used NLP to research the biomedical corpus. At BenevolentAI, she helped shape the discovery strategy for a number of programs, led the Age-Related Macular Degeneration and Glioblastoma drug discovery programmes and served as the interface between the technical and biological teams under the mentorship of Prof. Jackie Hunter.</p> <p>Born and raised in Pakistan, Rabia has a passion for supporting diversity in technology, and supporting initiatives focused on improving access to care for Schizophrenia and Dementia. <br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Samir Ounzain</h3> Senior Chief Executive Officer and Scientific Co-Founder, HAYA Therapeutics </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl13_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/222933.png?width=200&height=190&bgcolor=white&scale=canvas" alt="Samir Ounzain" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Samir Ounzain is a molecular biologist with over 15 years of experience exploring the dark matter of the genome and its roles in development and disease.<br /> Prior to founding HAYA Therapeutics, Samir was a Project Leader and Research Fellow at the Lausanne University Hospital (CHUV), where his research efforts directly led to the discovery of hundreds of novel heart-enriched lncRNAs, most notably the lncRNAs CARMEN, Meteor and Wisper.<br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Session Reserved for</h3> , BioPhorum </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl14_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/222963.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Session Reserved for" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Stefan Rathjen</h3> Senior Scientist Drug Delivery, Silence Therapeutics GmbH </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl15_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224017.png?width=200&height=190&bgcolor=white&scale=canvas" alt="Stefan Rathjen" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Stefan Rathjen studied biochemistry with majors in bioorganic chemistry and immunology at the university of Greifswald, Germany. Afterwards, Stefan did his PhD in molecular and cell biology at the Curie Institute and the “Université Paris-Saclay”, France, in which he studied endocytosis and intracellular processing of Shiga toxins. Since 2018, Stefan joined Silence Therapeutics in Berlin, Germany, where he works on improving Silence’s GOLD-platform, enabling extra-hepatic delivery of siRNA-conjugates, and the establishment of new experimental methodologies.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Thierry Dorval</h3> Head of Data Sciences & Data Management, Servier Pharmaceuticals </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl16_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/222882.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Thierry Dorval" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Thierry Dorval received a B.S. degree in theoretical physic and obtained a Ph.D. in image processing and artificial intelligence at Pierre & Marie Curie University, Paris, France. He then joined the Institut Pasteur Korea in 2005 first as researcher in biological image analysis then as a group leader specialized in High Content Screening applied to cellular differentiation as well as toxicity prediction. In 2012 he joined AstraZeneca, UK, where he was leading the Image and Data Analytics team. His activities were about developing and advising on quantitative image and data analysis solutions in support of high content phenotypic screens. <br /> In 2015 he joined Servier, France, first as leader of the High Content Screening group within CentEX CPCB and then as Head of Data Science Lab, working on phenotypic approaches to improve drug discovery pipeline efficiency using high content and machine learning strategies.<br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Thomas Thum</h3> Founder, Chief Scientific Officer and Chief Medical Officer, Cardior Pharmaceuticals GmbH </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl17_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/222885.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Thomas Thum" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Prof. Dr. Dr. med. Thomas Thum, Founder, managing director and CSO/CMO of Cardior Pharmaceuticals GmbH, is a key opinion leader in cardiac diseases and the development of RNA-based therapeutics. He has received numerous awards for his work. Thomas is a member of the editorial boards of the world’s most prestigious journals for cardiovascular research and an executive member of national and international research committees in the cardiovascular field. Since 2009 Thomas is Director of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hanover Medical School (MHH) and visiting professor at the National Heart and Lung Institute at Imperial College London since 2013. From 2021 to 2023 he was Director of the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hanover, Germany. Thomas Thum has authored over 500 scientific publications in renowned and field-leading journals and has filed over 50 patents, with many of them licensed and some already under clinical development.</p> </div> </div> <button title="Close (Esc)" type="button" class="mfp-close">×</button> </div> </div> <div style="margin-top:20px;"> <script> $(window).ready(function () { $("#sponsors-slider").owlCarousel({ items: 3, center: true, autoPlay: 3000, //Set AutoPlay to 3 seconds slideSpeed: 600, loop: true }); }); </script> <div id="ctl00_MainContent_sponsorsPartnersScroller_divSponsorsScroller" class="container sponsors-home"> <div class="col-md-12"> <h2> sponsors</h2> <div id="sponsors-slider" class="slider hidden partner-slider"> <div class="sponsor-elem"><a href="#pop-sponsor-single" class="open-popup-link "><img class="sponsor-image" src="/_media/partners/5591.jpg?width=210&height=100" alt="Asymchem" /></a><div class="hidden sponsor-name">Asymchem</div><div class="hidden sponsor-link">http://www.asymchem.com</div><div class="hidden sponsor-profile"><p>At Asymchem we are proud of the strides that we have made since our founding in 1998, providing one-stop services the world's top pharmaceutical companies. Driving our success is our commitment to continual optimization and investing in the future.<p> <p>Our solutions range from development stage to commercial stage, including R&D and cGMP production of advanced intermediates, APls, drug product, biologics, ADCs, payload-inkers, peptides, oligonucleotides, as well as quality control, non-clinical/clinical research services and regulatory affairs. Through strategic partnerships and calculated business growth, we have built an integrated service ecosystem, with the know how to help our clients get things done<p></div></div><div class="sponsor-elem"><a href="#pop-sponsor-single" class="open-popup-link "><img class="sponsor-image" src="/_media/partners/5589.png?width=210&height=100" alt="Aptamer Group" /></a><div class="hidden sponsor-name">Aptamer Group</div><div class="hidden sponsor-link">http://www.aptamergroup.com</div><div class="hidden sponsor-profile"><p>Aptamer Group develops custom affinity ligands for the life science industry through its proprietary Optimer® platform. Optimer binders are oligonucleotide-based affinity ligands that offer novel therapeutic solutions, from targeted delivery of diverse payloads to direct therapeutic moieties. They also support the drug pipeline with analytical and QC reagents. <p/> <p>Offering tuneable half-life, low immunogenicity, and the ability to hit new therapeutic targets, Optimer binders can enable new therapeutic breakthroughs to deliver science unlimited. <p/> </div></div><div class="sponsor-elem"><a href="#pop-sponsor-single" class="open-popup-link "><img class="sponsor-image" src="/_media/partners/5352.png?width=210&height=100" alt="ChemGenes" /></a><div class="hidden sponsor-name">ChemGenes</div><div class="hidden sponsor-link">https://www.chemgenes.com/</div><div class="hidden sponsor-profile"><p>ChemGenes, an ISO 9001 certified company established in 1981, is the industry leader in manufacturing oligonucleotide synthesis reagents and has consistently provided the highest quality phosphoramidites and solid supports in the market. Our facility, just outside of Boston/Cambridge Massachusetts USA, is setup for bulk manufacturing of therapeutic grade phosphoramidite and solid support DNA/RNA synthesis products for GMP grade oligonucleotide manufacturing. ChemGenes carries the widest variety of modified phosphoramidites and supports currently used in oligonucleotide synthesis including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based Probes and other areas of Nucleic Acid research. In addition, ChemGenes is expanding its custom oligonucleotide synthesis department specializing in the manufacture of ASOs, siRNA, gRNA, gapmers, aptamers, DNA based probes, and superior quality beads for Single Cell mRNA sequencing applications using Drop-Seq, Slide-seq, and Seq-Well methods. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.<p> </div></div> </div>  </div> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_programme"> <div class="programme2"> <script> $(document).ready(function () { $('.streamtabs a').click(function (event) { $(this).tab('show'); var target = $(this).attr('href'); $('html, body').animate({ scrollTop: $(target).offset().top }, 800); event.preventDefault(); return false; }); $('.daylist .nav-tabs > li > a, .daylist2 .nav-tabs > li > a').click(function (event) { var target = $(this).attr('href'); $(target).addClass('active').siblings().removeClass('active'); $('.daylist .nav-tabs .nav-link[href="' + target + '"], .daylist2 .nav-tabs .nav-link[href="' + target + '"]').parent().addClass('active').siblings().removeClass('active'); event.preventDefault(); }); }) function setActiveDay(dayNumber) { $('.daylist .nav-tabs li,.daylist2 .nav-tabs li').removeClass('active'); $('.daylist .nav-tabs li a[href*="#day_' + dayNumber + '"],.daylist2.nav - tabs li a[href *= "#day_' + dayNumber + '"]').parent().addClass('active'); } function updateURL(hash) { if (history.pushState) { history.pushState(null, null, hash); } else { location.hash = hash; } } </script> <h2>Conference agenda</h2> <div role="tabpanel" class="tabpanel"> <div class="daylist"> <ul class="nav nav-tabs" role="tablist" style="width:100%" > <li role="presentation" class="active"><a class="nav-link" href="#day_1" aria-controls="day_1" role="tab" data-toggle="tab" onclick="scrollToPosition(700);">Day One</a></li><li role="presentation" class=""><a class="nav-link" href="#day_2" aria-controls="day_2" role="tab" data-toggle="tab" onclick="scrollToPosition(700);">Day Two</a></li> </ul> </div>  <div id="daycontent" class="tab-content"> <div role="tabpanel" class="tab-pane active" id="day_1"><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">8:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Registration & Coffee</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Chair's Opening Remarks</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Harnessing innate mechanisms of gene activation for RNAa therapeutics</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/222878.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Nagy Habib" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Nagy Habib, </strong></span><span class="speaker-details">Professor of Surgery, Imperial College London, Co-Founder, <strong>MiNA, Apterna and Dawn Therapeutics</strong></span><div class="hidden speaker-profile"><p>For over three decades Nagy has been at the forefront of clinical research and clinical practise in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene therapy delivery. He was the first in Europe to perform a clinical trial with the use of adult CD34+ stem cells in patients with liver failure and stroke.<br /> Nagy is a founder and was the Head of R&D of Mina therapeutics whilst at Mina he was driving the development of saRNA drug (a new class of medicines) which is currently being trialled in patients with liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, Clinical Trials.gov ID NCT02716012) and in a second trial in patients with solid tumours (TIMEPOINT study, ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan.<br /> He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Currently he is the CEO of Apterna Limited, a company focussed on novel oligonucleotide delivery and Dawn Therapeutics specialising in gene therapy. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018).<br /> Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.</p></div><div class="topic-description"> <li>An update on RNAa development programs for previously undruggable targets</li> <li>Key finding and next steps from the latest RNA activation clinical results</li> <li>Extrahepatic oligonucleotide delivery: how has technology and R&D progressed in recent years and what does this mean for the industry</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:50</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Manufacturing therapeutic oligonucleotides – the challenges of scale, cost and sustainability</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/222879.png?width=180&height=180&bgcolor=white&scale=canvas" alt="David Tew" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>David Tew, </strong></span><span class="speaker-details">Senior Scientific Director, Enzyme Engineering and Biocatalysts (E2B), <strong>GSK</strong></span><div class="hidden speaker-profile"><p>David Tew is a Senior Scientific Director at GSK. David has 35 years of experience in the pharmaceutical industry including early drug discovery, mechanistic enzymology, assay development, reagent generation and the application of Synthetic Biology. Most recently David has been leading a project to apply Synthetic Biology to redesign the manufacture of therapeutic oligonucleotides. This has resulted in a platform approach to therapeutic oligonucleotide synthesis and manufacture that is both scalable and more sustainable than current approaches. <br /> In 2018 David was appointed as The Royal Society Entrepreneur in Residence at Bristol University working with BrisSynBio and the Bristol Biodesign Institute. David held this position until 2022.<br /> During the SARS-CoV-2 pandemic, David lead the innovation workstream for the Cambridge COVID-19 Testing Centre, a collaboration between AstraZeneca, GlaxoSmithKline and the University of Cambridge.<br />  </p></div><div class="topic-description"> <li>Solid phase vs liquid phase methods</li> <li>New chemistries for oligonucleotide synthesis</li> <li>The use of enzymes in oligonucleotide synthesis</li> <li>Thoughts on how these new methods will help to address cost and sustainability issues</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">10:30</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Morning Coffee</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">11:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Non-coding RNA-based therapeutics at the pulse of heart disease</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/222885.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Thomas Thum" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Thomas Thum, </strong></span><span class="speaker-details">Founder, Chief Scientific Officer and Chief Medical Officer, <strong>Cardior Pharmaceuticals GmbH</strong></span><div class="hidden speaker-profile"><p>Prof. Dr. Dr. med. Thomas Thum, Founder, managing director and CSO/CMO of Cardior Pharmaceuticals GmbH, is a key opinion leader in cardiac diseases and the development of RNA-based therapeutics. He has received numerous awards for his work. Thomas is a member of the editorial boards of the world’s most prestigious journals for cardiovascular research and an executive member of national and international research committees in the cardiovascular field. Since 2009 Thomas is Director of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hanover Medical School (MHH) and visiting professor at the National Heart and Lung Institute at Imperial College London since 2013. From 2021 to 2023 he was Director of the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hanover, Germany. Thomas Thum has authored over 500 scientific publications in renowned and field-leading journals and has filed over 50 patents, with many of them licensed and some already under clinical development.</p></div><div class="topic-description"> <li>Ongoing phase 2 trial in heart failure patients: How is the oligonucleotide R&D landscape accelerating forward for heart failure treatments?</li> <li>Cardior Pharmaceuticals/pharma company interaction: What this means for strengthened RNA-based pipelines for chronic populations</li> <li>Delving into further drug discovery pipelines in heart failure subgroups, where is research and funding still needed?</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">11:40</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Analytical strategies to ensure the quality of small synthetic antisense oligonucleotide and siRNA therapeutics in early development</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/222962.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Joanna Hemming Taylor" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Joanna Hemming Taylor, </strong></span><span class="speaker-details">Associate Principal Scientist, <strong>AstraZeneca</strong></span><div class="hidden speaker-profile"><p>Joanna Hemming Taylor graduated with a MChem in Chemistry with industrial experience from the University of Manchester in 2009, followed by a PhD in biophysical and computational chemistry from University College London with an emphasis on characterisation of lipids and peptides at the air-liquid interface. In 2014 Joanna joined AstraZeneca and has worked as an analytical project lead on multiple early phase clinical projects, from small molecule therapeutics to larger synthetics such as peptides and drug-dendrimer conjugates. Most recently, Joanna has been responsible for leading the analytical development of siRNA projects within Early Chemical Development.</p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">12:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Networking Lunch</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">13:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Reviewing industry progress and R&D for advanced oligonucleotide modalities</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/222878.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Nagy Habib" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Nagy Habib, </strong></span><span class="speaker-details">Professor of Surgery, Imperial College London, Co-Founder, <strong>MiNA, Apterna and Dawn Therapeutics</strong></span><div class="hidden speaker-profile"><p>For over three decades Nagy has been at the forefront of clinical research and clinical practise in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene therapy delivery. He was the first in Europe to perform a clinical trial with the use of adult CD34+ stem cells in patients with liver failure and stroke.<br /> Nagy is a founder and was the Head of R&D of Mina therapeutics whilst at Mina he was driving the development of saRNA drug (a new class of medicines) which is currently being trialled in patients with liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, Clinical Trials.gov ID NCT02716012) and in a second trial in patients with solid tumours (TIMEPOINT study, ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan.<br /> He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Currently he is the CEO of Apterna Limited, a company focussed on novel oligonucleotide delivery and Dawn Therapeutics specialising in gene therapy. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018).<br /> Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.</p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/222880.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Peter Smith" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Peter Smith, </strong></span><span class="speaker-details">Director, New Modalities Chemistry, <strong>AstraZeneca</strong></span><div class="hidden speaker-profile"><p>Peter Smith is currently Director, New Modalities Chemistry within AstraZeneca’s Early Chemical Development group based in Macclesfield, UK. Peter has a background in synthetic organic chemistry (BSc Hons Glasgow, PhD Heriot-Watt, PDRA Sussex) and has worked at AstraZeneca for over 20 years in a variety of chemistry roles. During 2016, Peter took the position of early-phase Oligonucleotide chemistry lead, responsible for chemical development and drug substance manufacturing of AZ’s early-phase oligonucleotide clinical portfolio, and since then has progressed to his current role where he has accountability across the fields of oligonucleotides, peptides, ADC’s and ionizable lipids.</p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/222882.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Thierry Dorval" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Thierry Dorval, </strong></span><span class="speaker-details">Head of Data Sciences & Data Management, <strong>Servier Pharmaceuticals</strong></span><div class="hidden speaker-profile"><p>Thierry Dorval received a B.S. degree in theoretical physic and obtained a Ph.D. in image processing and artificial intelligence at Pierre & Marie Curie University, Paris, France. He then joined the Institut Pasteur Korea in 2005 first as researcher in biological image analysis then as a group leader specialized in High Content Screening applied to cellular differentiation as well as toxicity prediction. In 2012 he joined AstraZeneca, UK, where he was leading the Image and Data Analytics team. His activities were about developing and advising on quantitative image and data analysis solutions in support of high content phenotypic screens. <br /> In 2015 he joined Servier, France, first as leader of the High Content Screening group within CentEX CPCB and then as Head of Data Science Lab, working on phenotypic approaches to improve drug discovery pipeline efficiency using high content and machine learning strategies.<br />  </p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/225480.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Marco Mina" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Marco Mina, </strong></span><span class="speaker-details">Director, Head of Comp Bio and Data Science, <strong>HAYA Therapeutics</strong></span><div class="hidden speaker-profile"><p>Marco Mina is a computer scientist and computational biologist with 10+ years’ experience in Data Science, Bioinformatics and Computational Biology. After receiving his doctoral degree in Information Engineering from the University of Padova (Italy), Marco held a postdoctoral position in Cancer Genomics at the University of Lausanne, focusing on functional dependencies between cancer mutations and their therapeutic actionability. He later transitioned to industrial research at SOPHiA Genetics, leading a team focusing on variant annotation and pathogenicity prediction for the interpretation of patient molecular data. At HAYA Therapeutics, Marco is leading the Data Science and Computational Biology unit. His team focuses on multiple R&D aspects of the target discovery and drug discovery and nomination platforms. During his career, Marco published more than 20 articles (10+ as first co-author, > 7000 citations) in world-leading, peer-reviewed journals including Cell, Cancer Cell and Nature Genetics.</p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">14:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Mapping the Druggable Transcriptome – Exploring the Intersection of AI, synthetic Biology, and Drug Discovery</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/222881.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Rabia Khan" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Rabia Khan, </strong></span><span class="speaker-details">Founder & CEO, <strong>Serna.bio</strong></span><div class="hidden speaker-profile"><p>Rabia Khan, PhD (Immuno Genetics, MBA) is the founder and CEO of Serna Bio, a YC-backed biotech building the world's first map of the druggable transcriptome. She is a member of the Board of Trustees for the UK Dementia Research Institute, and an advisor to No Label Ventures, a fund investing in immigrant founders in the UK and EU.</p> <p>Prior to founding Serna Bio, Rabia was Managing Director, Discovery Sciences at Sensyne Health plc (now - Arctoris Data) where she established the scientific strategy, built the data science and discovery teams by recruiting and leading a team of 50 machine learning and clinical researchers, delivering on a number of significant pharma partnerships including Bayer, BMS, Roche and Alexion.</p> <p>She also held senior roles at BenevolentAI and Meta (acquired by Chan Zuckerberg BioHub). At Meta (previously Sciencescape), she was pivotal in the partnership with the Intelligence Advanced Research Projects Activity (IARPA) to acquire horizon-scanning technology that used NLP to research the biomedical corpus. At BenevolentAI, she helped shape the discovery strategy for a number of programs, led the Age-Related Macular Degeneration and Glioblastoma drug discovery programmes and served as the interface between the technical and biological teams under the mentorship of Prof. Jackie Hunter.</p> <p>Born and raised in Pakistan, Rabia has a passion for supporting diversity in technology, and supporting initiatives focused on improving access to care for Schizophrenia and Dementia. <br />  </p></div><div class="topic-description"> <li>Why RNA? Limits of protein-focused drug discovery</li> <li>The druggable transcriptome: mapping structure-functional relationships at scale</li> <li>Leveraging the new RNA world for drug discovery – unlocking classically undruggable proteins and unexplored potential therapeutic targets</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">14:40</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Afternoon Tea</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">15:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">In Vivo tLNP Platform – Transforming Cell Therapy</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/222886.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Priya Karmali" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Priya Karmali, </strong></span><span class="speaker-details">Chief Technology Officer, <strong>Capstan Therapeutics</strong></span><div class="hidden speaker-profile"><p>Priya Karmali, PhD. is Chief Technology Officer at Capstan Therapeutics and leads all aspects of technology development. Priya has over 20 years of experience in the field of lipid nanoparticle delivered nucleic acid therapeutics from discovery through development. Prior to Capstan, Priya served as Vice President of Technology Innovation and Development at Arcturus Therapeutics. Previously, Priya held positions of increasing responsibility at Regulus Therapeutics and Nitto. Priya has a PhD in Chemistry from Indian Institute of Chemical Technology (India) where her doctoral research was focused on development of novel liposomal nucleic acid delivery systems for use in non-viral gene therapy and DNA vaccination. She pursued her postdoctoral research at Sanford-Burnham-Preby’s-Medical Discovery Institute, La Jolla, CA focusing on developing targeted nanoparticles for drug delivery. Priya is an author and co-inventor on over 70 publications and patents in the field.</p></div><div class="topic-description"> <li>Using LNP for in vivo CAR-T and cell reprogramming</li> <li>Payload considerations and platform approaches</li> <li>The untapped potentials of LNP-CAR for curative immunotherapies including fibrosis, autoimmune etc</li> <li>Scaling this up into a proven and viable platform</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">15:50</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Novel Lipid Technology Platforms for RNA Therapeutics and Vaccines</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/silhouette_M.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Heinrich Haas" /></a></div></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Heinrich Haas, </strong></span><span class="speaker-details">Chief Technology Officer, <strong>NeoVac</strong></span><div class="topic-description"> <li>To fully exploit the potential of nucleotide-based pharmaceuticals, tailored delivery systems are required. </li> <li>Key tasks comprise control of activity, targeting selectivity and immunogenicity.</li> <li>Careful selection of lipids and lipid compositions allows to design nanoparticles for a given purpose</li> <li>In-depth analytics and control strategies are of great importance for successful development </li> <li>Here we present examples for controlled assembly for improved mRNA nanoparticle formats</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">16:30</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Chair’s Closing Remarks and Close of Day One</h3></div></div></div></div></div><div role="tabpanel" class="tab-pane" id="day_2"><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">8:30</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Registration & Coffee</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Chairman's Opening Remarks</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Data Driven Optimization of Oligonucleotide Sequence Design</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/222882.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Thierry Dorval" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Thierry Dorval, </strong></span><span class="speaker-details">Head of Data Sciences & Data Management, <strong>Servier Pharmaceuticals</strong></span><div class="hidden speaker-profile"><p>Thierry Dorval received a B.S. degree in theoretical physic and obtained a Ph.D. in image processing and artificial intelligence at Pierre & Marie Curie University, Paris, France. He then joined the Institut Pasteur Korea in 2005 first as researcher in biological image analysis then as a group leader specialized in High Content Screening applied to cellular differentiation as well as toxicity prediction. In 2012 he joined AstraZeneca, UK, where he was leading the Image and Data Analytics team. His activities were about developing and advising on quantitative image and data analysis solutions in support of high content phenotypic screens. <br /> In 2015 he joined Servier, France, first as leader of the High Content Screening group within CentEX CPCB and then as Head of Data Science Lab, working on phenotypic approaches to improve drug discovery pipeline efficiency using high content and machine learning strategies.<br />  </p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:50</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">New ways of transporting API – technologies for producing, modifying and transporting nanoparticles</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/225479.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Christoph Hein" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Christoph Hein, </strong></span><span class="speaker-details">Division Director, Ultra- and Highprecision Technology, <strong>Fraunhofer IPK</strong></span><div class="hidden speaker-profile"><p>Dr. Christoph Hein is Director of the Ultra- and High-Precision Technology Division at the Fraunhofer IPK in Berlin. He studied biomedical engineering at the Technical University of Berlin and completed his doctorate in the field of micro-optical structures. At Fraunhofer IPK, he and his team are researching advanced technologies for the production, modification and transport of nanoparticles for applications in the field of oligonucleotide therapeutics and delivery.</p></div><div class="topic-description"> <li>Encapsulation technologies</li> <li>Modification and stabilization of nanoparticles</li> <li>Methods for nanoparticle transport</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">10:30</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Morning Coffee</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">11:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Identification and validation of non-coding pharmacological targets</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/silhouette_M.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Alessandro Bonetti" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Alessandro Bonetti, </strong></span><span class="speaker-details">Principal Scientist, R&D Biopharmaceuticals, <strong>AstraZeneca</strong></span><div class="hidden speaker-profile"><p>Dr. Alessandro Bonetti obtained his Master degree in Medical Biotechnologies at the University of Naples in 2001 and moved to Helsinki for his PhD studies where he investigated the genetic prediposition to multiple sclerosis in Nordic populations. He then moved to RIKEN Yokohama to study the biological role of long non-coding. During that time he developed numerous technologies to identify the functional relevance of non-coding transcripts in physiological and pathological conditions. Subsequently he joined AstraZeneca to lead the transcriptomic studies in the Oligonucleotide platform. In October 2022 he was appointed Principal Scientist to lead the non-coding initiative in AZ.</p></div><div class="topic-description"> <li>Overview of the non-coding field</li> <li>Non-coding elements as novel pharmacological targets</li> <li>Developing a technological pipeline for identificaiton and validation of non-coding pharmacological targets</li> <li>RNA therapeuthics targeting non-coding elements</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">11:40</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Improving target specificity and delivery technologies for oligonucleotide therapeutics</h3></div></div></div><div class="keynote-speaker clearfix"><div class="col-xs-2" style="float: left; padding-left:5px"></div><div class="col-xs-10" style="overflow:auto;"><div class="topic-description"> <li>Updates in LNP technologies and viral vectors for targeted oligonucleotide delivery</li> <li>Extrahepatic delivery: how far have we come and what is still needed to meet industry acceleration</li> <li>Looking to the future: what lies ahead for technologies to improve target specificity of ASO delivery?</li> </div></div></p></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/silhouette_M.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Alessandro Bonetti" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Alessandro Bonetti, </strong></span><span class="speaker-details">Principal Scientist, R&D Biopharmaceuticals, <strong>AstraZeneca</strong></span><div class="hidden speaker-profile"><p>Dr. Alessandro Bonetti obtained his Master degree in Medical Biotechnologies at the University of Naples in 2001 and moved to Helsinki for his PhD studies where he investigated the genetic prediposition to multiple sclerosis in Nordic populations. He then moved to RIKEN Yokohama to study the biological role of long non-coding. During that time he developed numerous technologies to identify the functional relevance of non-coding transcripts in physiological and pathological conditions. Subsequently he joined AstraZeneca to lead the transcriptomic studies in the Oligonucleotide platform. In October 2022 he was appointed Principal Scientist to lead the non-coding initiative in AZ.</p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224017.png?width=180&height=180&bgcolor=white&scale=canvas" alt="Stefan Rathjen" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Stefan Rathjen, </strong></span><span class="speaker-details">Senior Scientist Drug Delivery, <strong>Silence Therapeutics GmbH</strong></span><div class="hidden speaker-profile"><p>Stefan Rathjen studied biochemistry with majors in bioorganic chemistry and immunology at the university of Greifswald, Germany. Afterwards, Stefan did his PhD in molecular and cell biology at the Curie Institute and the “Université Paris-Saclay”, France, in which he studied endocytosis and intracellular processing of Shiga toxins. Since 2018, Stefan joined Silence Therapeutics in Berlin, Germany, where he works on improving Silence’s GOLD-platform, enabling extra-hepatic delivery of siRNA-conjugates, and the establishment of new experimental methodologies.</p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/225479.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Christoph Hein" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Christoph Hein, </strong></span><span class="speaker-details">Division Director, Ultra- and Highprecision Technology, <strong>Fraunhofer IPK</strong></span><div class="hidden speaker-profile"><p>Dr. Christoph Hein is Director of the Ultra- and High-Precision Technology Division at the Fraunhofer IPK in Berlin. He studied biomedical engineering at the Technical University of Berlin and completed his doctorate in the field of micro-optical structures. At Fraunhofer IPK, he and his team are researching advanced technologies for the production, modification and transport of nanoparticles for applications in the field of oligonucleotide therapeutics and delivery.</p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/222878.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Nagy Habib" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Nagy Habib, </strong></span><span class="speaker-details">Professor of Surgery, Imperial College London, Co-Founder, <strong>MiNA, Apterna and Dawn Therapeutics</strong></span><div class="hidden speaker-profile"><p>For over three decades Nagy has been at the forefront of clinical research and clinical practise in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene therapy delivery. He was the first in Europe to perform a clinical trial with the use of adult CD34+ stem cells in patients with liver failure and stroke.<br /> Nagy is a founder and was the Head of R&D of Mina therapeutics whilst at Mina he was driving the development of saRNA drug (a new class of medicines) which is currently being trialled in patients with liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, Clinical Trials.gov ID NCT02716012) and in a second trial in patients with solid tumours (TIMEPOINT study, ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan.<br /> He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Currently he is the CEO of Apterna Limited, a company focussed on novel oligonucleotide delivery and Dawn Therapeutics specialising in gene therapy. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018).<br /> Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.</p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">12:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Networking Lunch</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">13:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Enhancing Bioavailability of siRNA: A Focus on Stability and Circulation Time!</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224017.png?width=180&height=180&bgcolor=white&scale=canvas" alt="Stefan Rathjen" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Stefan Rathjen, </strong></span><span class="speaker-details">Senior Scientist Drug Delivery, <strong>Silence Therapeutics GmbH</strong></span><div class="hidden speaker-profile"><p>Stefan Rathjen studied biochemistry with majors in bioorganic chemistry and immunology at the university of Greifswald, Germany. Afterwards, Stefan did his PhD in molecular and cell biology at the Curie Institute and the “Université Paris-Saclay”, France, in which he studied endocytosis and intracellular processing of Shiga toxins. Since 2018, Stefan joined Silence Therapeutics in Berlin, Germany, where he works on improving Silence’s GOLD-platform, enabling extra-hepatic delivery of siRNA-conjugates, and the establishment of new experimental methodologies.</p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">14:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">The dark genome as the next revolution in drug discovery</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/225480.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Marco Mina" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Marco Mina, </strong></span><span class="speaker-details">Director, Head of Comp Bio and Data Science, <strong>HAYA Therapeutics</strong></span><div class="hidden speaker-profile"><p>Marco Mina is a computer scientist and computational biologist with 10+ years’ experience in Data Science, Bioinformatics and Computational Biology. After receiving his doctoral degree in Information Engineering from the University of Padova (Italy), Marco held a postdoctoral position in Cancer Genomics at the University of Lausanne, focusing on functional dependencies between cancer mutations and their therapeutic actionability. He later transitioned to industrial research at SOPHiA Genetics, leading a team focusing on variant annotation and pathogenicity prediction for the interpretation of patient molecular data. At HAYA Therapeutics, Marco is leading the Data Science and Computational Biology unit. His team focuses on multiple R&D aspects of the target discovery and drug discovery and nomination platforms. During his career, Marco published more than 20 articles (10+ as first co-author, > 7000 citations) in world-leading, peer-reviewed journals including Cell, Cancer Cell and Nature Genetics.</p></div><div class="topic-description"> <li>What is the ‘dark genome’ actually about</li> <li>Decoding ‘junk DNA’ and the potential toolbox of IncRNA-targeting therapeutics</li> <li>The promise compared to traditional approaches</li> <li>Drugging the dark genome for treating fibrotic diseases</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">14:40</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Afternoon Tea</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">15:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Recent Advances in the Development of Splice-Switching Oligonucleotides for CNS Diseases</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/222887.png?width=180&height=180&bgcolor=white&scale=canvas" alt="Daniel Elbaum" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Daniel Elbaum, </strong></span><span class="speaker-details">Chief Scientific Officer, <strong>QurAlis</strong></span><div class="hidden speaker-profile"><p>Daniel (Dan) Elbaum, PhD, is a drug discovery and development leader with nearly three decades of experience. He thrives on making new discoveries and connections and has made significant contributions in the fields of oncology, inflammation, and orphan diseases. He has worked in large organizations including Pfizer and Amgen, as well as several start-up companies including Kinetix Pharmaceuticals and FoldRx Pharmaceuticals (acquired by Pfizer). He was senior director, chemistry and portfolio management, and co-head of the research and non-clinical development group at Retrophin. To keep abreast of cutting-edge research, he actively maintains close ties with the academic and start-up communities.<br /> <br /> Dan earned his PhD and undergraduate degrees in chemistry from Harvard University, and conducted postdoctoral research at the University of Pennsylvania. An inventor on more than 25 patents and an author on more than 15 peer-reviewed publications, Dan is a mentor in the Kindle Mentors Program at Boston University and a longstanding member of the American Chemical Society and the Association for the Advancement of Science.</p></div><div class="topic-description"> <li>PreRNA mis-splicing is a recurring theme in neurodegenerative diseases.</li> <li>Splice switching ASOs provide a powerful modality to correct these errors. </li> <li>QurAlis’ FlexASO™ platform enables the construction of splice switching ASOs with enhanced potency, safety, and biodistribution properties.</li> <li>This platform generally and in the context of our discovery programs will be discussed</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">15:50</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Chairman’s Closing Remarks and Close of Day Two</h3></div></div></div></div></div> </div>  <div class="daylist2"> <ul class="nav nav-tabs" role="tablist" > <li role="presentation" class="active"><a class="nav-link" href="#day_1" aria-controls="day_1" role="tab" data-toggle="tab" onclick="scrollToPosition(700);">Day One</a></li><li role="presentation" class=""><a class="nav-link" href="#day_2" aria-controls="day_2" role="tab" data-toggle="tab" onclick="scrollToPosition(700);">Day Two</a></li> </ul> </div> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_speakers"> <div id="speaker-grid"> <div id="pop-speakers-all" class="container-fluid" style="margin-bottom: 20px;"> <br> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl01_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/silhouette_M.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Alessandro Bonetti" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Alessandro Bonetti</a></div> <div style="margin-top:5px"">Principal Scientist, R&D Biopharmaceuticals</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">AstraZeneca</div> <div class="hidden speaker-details">Principal Scientist, R&D Biopharmaceuticals, AstraZeneca</div> <div class="hidden speaker-profile"><p>Dr. Alessandro Bonetti obtained his Master degree in Medical Biotechnologies at the University of Naples in 2001 and moved to Helsinki for his PhD studies where he investigated the genetic prediposition to multiple sclerosis in Nordic populations. He then moved to RIKEN Yokohama to study the biological role of long non-coding. During that time he developed numerous technologies to identify the functional relevance of non-coding transcripts in physiological and pathological conditions. Subsequently he joined AstraZeneca to lead the transcriptomic studies in the Oligonucleotide platform. In October 2022 he was appointed Principal Scientist to lead the non-coding initiative in AZ.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl02_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/225479.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Christoph Hein" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Christoph Hein</a></div> <div style="margin-top:5px"">Division Director, Ultra- and Highprecision Technology</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Fraunhofer IPK</div> <div class="hidden speaker-details">Division Director, Ultra- and Highprecision Technology, Fraunhofer IPK</div> <div class="hidden speaker-profile"><p>Dr. Christoph Hein is Director of the Ultra- and High-Precision Technology Division at the Fraunhofer IPK in Berlin. He studied biomedical engineering at the Technical University of Berlin and completed his doctorate in the field of micro-optical structures. At Fraunhofer IPK, he and his team are researching advanced technologies for the production, modification and transport of nanoparticles for applications in the field of oligonucleotide therapeutics and delivery.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl03_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/222887.png?width=250&height=250&bgcolor=white&scale=canvas" alt="Daniel Elbaum" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Daniel Elbaum</a></div> <div style="margin-top:5px"">Chief Scientific Officer</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">QurAlis</div> <div class="hidden speaker-details">Chief Scientific Officer, QurAlis</div> <div class="hidden speaker-profile"><p>Daniel (Dan) Elbaum, PhD, is a drug discovery and development leader with nearly three decades of experience. He thrives on making new discoveries and connections and has made significant contributions in the fields of oncology, inflammation, and orphan diseases. He has worked in large organizations including Pfizer and Amgen, as well as several start-up companies including Kinetix Pharmaceuticals and FoldRx Pharmaceuticals (acquired by Pfizer). He was senior director, chemistry and portfolio management, and co-head of the research and non-clinical development group at Retrophin. To keep abreast of cutting-edge research, he actively maintains close ties with the academic and start-up communities.<br /> <br /> Dan earned his PhD and undergraduate degrees in chemistry from Harvard University, and conducted postdoctoral research at the University of Pennsylvania. An inventor on more than 25 patents and an author on more than 15 peer-reviewed publications, Dan is a mentor in the Kindle Mentors Program at Boston University and a longstanding member of the American Chemical Society and the Association for the Advancement of Science.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl04_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/222949.png?width=250&height=250&bgcolor=white&scale=canvas" alt="David Evans" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">David Evans</a></div> <div style="margin-top:5px"">CSO</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Sirnaomics, Inc</div> <div class="hidden speaker-details">CSO, Sirnaomics, Inc</div> <div class="hidden speaker-profile"><p>David M. Evans, Ph.D, Co-founder and CSO, Sirnaomics Inc. Gaithersburg, MD. Dr. Evans has over 25 years experience in drug target and small molecule discovery for oncology, infectious diseases and CNS therapeutics. He has been involved in the RNAi field since 2003. As Head of Drug Discovery for the Cancer Drug Development Lab for TGEN and as Sr. Director, RNAi Discovery and Therapeutic Services group, Dharmacon group, Thermo Fisher Scientific (TFS), he built HTS operations to identify targets that synergized with known oncology therapeutics. In 2008 Davidwas a cofounder of Sirnaomics and has led the R&D group with afocus on using siRNAs as therapeutics in their own right. Sirnaomics now has several candidates in clinical testing and a<br /> rich pipeline of preclinical products. David received his BSc(1983) and PhD (1987) from Imperial College, London and has published a number of peer reviewed papers and review articles.<br />  </p></div> </div> </div> </div> </div> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl05_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/222879.png?width=250&height=250&bgcolor=white&scale=canvas" alt="David Tew" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">David Tew</a></div> <div style="margin-top:5px"">Senior Scientific Director, Enzyme Engineering and Biocatalysts (E2B)</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">GSK</div> <div class="hidden speaker-details">Senior Scientific Director, Enzyme Engineering and Biocatalysts (E2B), GSK</div> <div class="hidden speaker-profile"><p>David Tew is a Senior Scientific Director at GSK. David has 35 years of experience in the pharmaceutical industry including early drug discovery, mechanistic enzymology, assay development, reagent generation and the application of Synthetic Biology. Most recently David has been leading a project to apply Synthetic Biology to redesign the manufacture of therapeutic oligonucleotides. This has resulted in a platform approach to therapeutic oligonucleotide synthesis and manufacture that is both scalable and more sustainable than current approaches. <br /> In 2018 David was appointed as The Royal Society Entrepreneur in Residence at Bristol University working with BrisSynBio and the Bristol Biodesign Institute. David held this position until 2022.<br /> During the SARS-CoV-2 pandemic, David lead the innovation workstream for the Cambridge COVID-19 Testing Centre, a collaboration between AstraZeneca, GlaxoSmithKline and the University of Cambridge.<br />  </p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl06_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/silhouette_M.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Heinrich Haas" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Heinrich Haas</a></div> <div style="margin-top:5px"">Chief Technology Officer</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">NeoVac</div> <div class="hidden speaker-details">Chief Technology Officer, NeoVac</div> <div class="hidden speaker-profile"></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl07_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/222962.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Joanna Hemming Taylor" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Joanna Hemming Taylor</a></div> <div style="margin-top:5px"">Associate Principal Scientist</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">AstraZeneca</div> <div class="hidden speaker-details">Associate Principal Scientist, AstraZeneca</div> <div class="hidden speaker-profile"><p>Joanna Hemming Taylor graduated with a MChem in Chemistry with industrial experience from the University of Manchester in 2009, followed by a PhD in biophysical and computational chemistry from University College London with an emphasis on characterisation of lipids and peptides at the air-liquid interface. In 2014 Joanna joined AstraZeneca and has worked as an analytical project lead on multiple early phase clinical projects, from small molecule therapeutics to larger synthetics such as peptides and drug-dendrimer conjugates. Most recently, Joanna has been responsible for leading the analytical development of siRNA projects within Early Chemical Development.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl08_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/225480.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Marco Mina" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Marco Mina</a></div> <div style="margin-top:5px"">Director, Head of Comp Bio and Data Science</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">HAYA Therapeutics</div> <div class="hidden speaker-details">Director, Head of Comp Bio and Data Science, HAYA Therapeutics</div> <div class="hidden speaker-profile"><p>Marco Mina is a computer scientist and computational biologist with 10+ years’ experience in Data Science, Bioinformatics and Computational Biology. After receiving his doctoral degree in Information Engineering from the University of Padova (Italy), Marco held a postdoctoral position in Cancer Genomics at the University of Lausanne, focusing on functional dependencies between cancer mutations and their therapeutic actionability. He later transitioned to industrial research at SOPHiA Genetics, leading a team focusing on variant annotation and pathogenicity prediction for the interpretation of patient molecular data. At HAYA Therapeutics, Marco is leading the Data Science and Computational Biology unit. His team focuses on multiple R&D aspects of the target discovery and drug discovery and nomination platforms. During his career, Marco published more than 20 articles (10+ as first co-author, > 7000 citations) in world-leading, peer-reviewed journals including Cell, Cancer Cell and Nature Genetics.</p></div> </div> </div> </div> </div> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl09_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/222878.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Nagy Habib" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Nagy Habib</a></div> <div style="margin-top:5px"">Professor of Surgery, Imperial College London, Co-Founder</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">MiNA, Apterna and Dawn Therapeutics</div> <div class="hidden speaker-details">Professor of Surgery, Imperial College London, Co-Founder, MiNA, Apterna and Dawn Therapeutics</div> <div class="hidden speaker-profile"><p>For over three decades Nagy has been at the forefront of clinical research and clinical practise in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene therapy delivery. He was the first in Europe to perform a clinical trial with the use of adult CD34+ stem cells in patients with liver failure and stroke.<br /> Nagy is a founder and was the Head of R&D of Mina therapeutics whilst at Mina he was driving the development of saRNA drug (a new class of medicines) which is currently being trialled in patients with liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, Clinical Trials.gov ID NCT02716012) and in a second trial in patients with solid tumours (TIMEPOINT study, ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan.<br /> He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Currently he is the CEO of Apterna Limited, a company focussed on novel oligonucleotide delivery and Dawn Therapeutics specialising in gene therapy. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018).<br /> Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl10_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/222880.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Peter Smith" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Peter Smith</a></div> <div style="margin-top:5px"">Director, New Modalities Chemistry</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">AstraZeneca</div> <div class="hidden speaker-details">Director, New Modalities Chemistry, AstraZeneca</div> <div class="hidden speaker-profile"><p>Peter Smith is currently Director, New Modalities Chemistry within AstraZeneca’s Early Chemical Development group based in Macclesfield, UK. Peter has a background in synthetic organic chemistry (BSc Hons Glasgow, PhD Heriot-Watt, PDRA Sussex) and has worked at AstraZeneca for over 20 years in a variety of chemistry roles. During 2016, Peter took the position of early-phase Oligonucleotide chemistry lead, responsible for chemical development and drug substance manufacturing of AZ’s early-phase oligonucleotide clinical portfolio, and since then has progressed to his current role where he has accountability across the fields of oligonucleotides, peptides, ADC’s and ionizable lipids.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl11_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/222886.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Priya Karmali" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Priya Karmali</a></div> <div style="margin-top:5px"">Chief Technology Officer</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Capstan Therapeutics</div> <div class="hidden speaker-details">Chief Technology Officer, Capstan Therapeutics</div> <div class="hidden speaker-profile"><p>Priya Karmali, PhD. is Chief Technology Officer at Capstan Therapeutics and leads all aspects of technology development. Priya has over 20 years of experience in the field of lipid nanoparticle delivered nucleic acid therapeutics from discovery through development. Prior to Capstan, Priya served as Vice President of Technology Innovation and Development at Arcturus Therapeutics. Previously, Priya held positions of increasing responsibility at Regulus Therapeutics and Nitto. Priya has a PhD in Chemistry from Indian Institute of Chemical Technology (India) where her doctoral research was focused on development of novel liposomal nucleic acid delivery systems for use in non-viral gene therapy and DNA vaccination. She pursued her postdoctoral research at Sanford-Burnham-Preby’s-Medical Discovery Institute, La Jolla, CA focusing on developing targeted nanoparticles for drug delivery. Priya is an author and co-inventor on over 70 publications and patents in the field.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl12_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/222881.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Rabia Khan" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Rabia Khan</a></div> <div style="margin-top:5px"">Founder & CEO</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Serna.bio</div> <div class="hidden speaker-details">Founder & CEO, Serna.bio</div> <div class="hidden speaker-profile"><p>Rabia Khan, PhD (Immuno Genetics, MBA) is the founder and CEO of Serna Bio, a YC-backed biotech building the world's first map of the druggable transcriptome. She is a member of the Board of Trustees for the UK Dementia Research Institute, and an advisor to No Label Ventures, a fund investing in immigrant founders in the UK and EU.</p> <p>Prior to founding Serna Bio, Rabia was Managing Director, Discovery Sciences at Sensyne Health plc (now - Arctoris Data) where she established the scientific strategy, built the data science and discovery teams by recruiting and leading a team of 50 machine learning and clinical researchers, delivering on a number of significant pharma partnerships including Bayer, BMS, Roche and Alexion.</p> <p>She also held senior roles at BenevolentAI and Meta (acquired by Chan Zuckerberg BioHub). At Meta (previously Sciencescape), she was pivotal in the partnership with the Intelligence Advanced Research Projects Activity (IARPA) to acquire horizon-scanning technology that used NLP to research the biomedical corpus. At BenevolentAI, she helped shape the discovery strategy for a number of programs, led the Age-Related Macular Degeneration and Glioblastoma drug discovery programmes and served as the interface between the technical and biological teams under the mentorship of Prof. Jackie Hunter.</p> <p>Born and raised in Pakistan, Rabia has a passion for supporting diversity in technology, and supporting initiatives focused on improving access to care for Schizophrenia and Dementia. <br />  </p></div> </div> </div> </div> </div> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl13_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/222933.png?width=250&height=250&bgcolor=white&scale=canvas" alt="Samir Ounzain" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Samir Ounzain</a></div> <div style="margin-top:5px"">Senior Chief Executive Officer and Scientific Co-Founder</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">HAYA Therapeutics</div> <div class="hidden speaker-details">Senior Chief Executive Officer and Scientific Co-Founder, HAYA Therapeutics</div> <div class="hidden speaker-profile"><p>Samir Ounzain is a molecular biologist with over 15 years of experience exploring the dark matter of the genome and its roles in development and disease.<br /> Prior to founding HAYA Therapeutics, Samir was a Project Leader and Research Fellow at the Lausanne University Hospital (CHUV), where his research efforts directly led to the discovery of hundreds of novel heart-enriched lncRNAs, most notably the lncRNAs CARMEN, Meteor and Wisper.<br />  </p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl14_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/222963.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Session Reserved for" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Session Reserved for</a></div> <div style="margin-top:5px""></div> <div style="margin-top:5px; font-weight:700; font-color: #000;">BioPhorum</div> <div class="hidden speaker-details">, BioPhorum</div> <div class="hidden speaker-profile"></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl15_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224017.png?width=250&height=250&bgcolor=white&scale=canvas" alt="Stefan Rathjen" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Stefan Rathjen</a></div> <div style="margin-top:5px"">Senior Scientist Drug Delivery</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Silence Therapeutics GmbH</div> <div class="hidden speaker-details">Senior Scientist Drug Delivery, Silence Therapeutics GmbH</div> <div class="hidden speaker-profile"><p>Stefan Rathjen studied biochemistry with majors in bioorganic chemistry and immunology at the university of Greifswald, Germany. Afterwards, Stefan did his PhD in molecular and cell biology at the Curie Institute and the “Université Paris-Saclay”, France, in which he studied endocytosis and intracellular processing of Shiga toxins. Since 2018, Stefan joined Silence Therapeutics in Berlin, Germany, where he works on improving Silence’s GOLD-platform, enabling extra-hepatic delivery of siRNA-conjugates, and the establishment of new experimental methodologies.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl16_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/222882.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Thierry Dorval" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Thierry Dorval</a></div> <div style="margin-top:5px"">Head of Data Sciences & Data Management</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Servier Pharmaceuticals</div> <div class="hidden speaker-details">Head of Data Sciences & Data Management, Servier Pharmaceuticals</div> <div class="hidden speaker-profile"><p>Thierry Dorval received a B.S. degree in theoretical physic and obtained a Ph.D. in image processing and artificial intelligence at Pierre & Marie Curie University, Paris, France. He then joined the Institut Pasteur Korea in 2005 first as researcher in biological image analysis then as a group leader specialized in High Content Screening applied to cellular differentiation as well as toxicity prediction. In 2012 he joined AstraZeneca, UK, where he was leading the Image and Data Analytics team. His activities were about developing and advising on quantitative image and data analysis solutions in support of high content phenotypic screens. <br /> In 2015 he joined Servier, France, first as leader of the High Content Screening group within CentEX CPCB and then as Head of Data Science Lab, working on phenotypic approaches to improve drug discovery pipeline efficiency using high content and machine learning strategies.<br />  </p></div> </div> </div> </div> </div> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl17_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/222885.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Thomas Thum" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Thomas Thum</a></div> <div style="margin-top:5px"">Founder, Chief Scientific Officer and Chief Medical Officer</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Cardior Pharmaceuticals GmbH</div> <div class="hidden speaker-details">Founder, Chief Scientific Officer and Chief Medical Officer, Cardior Pharmaceuticals GmbH</div> <div class="hidden speaker-profile"><p>Prof. Dr. Dr. med. Thomas Thum, Founder, managing director and CSO/CMO of Cardior Pharmaceuticals GmbH, is a key opinion leader in cardiac diseases and the development of RNA-based therapeutics. He has received numerous awards for his work. Thomas is a member of the editorial boards of the world’s most prestigious journals for cardiovascular research and an executive member of national and international research committees in the cardiovascular field. Since 2009 Thomas is Director of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hanover Medical School (MHH) and visiting professor at the National Heart and Lung Institute at Imperial College London since 2013. From 2021 to 2023 he was Director of the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hanover, Germany. Thomas Thum has authored over 500 scientific publications in renowned and field-leading journals and has filed over 50 patents, with many of them licensed and some already under clinical development.</p></div> </div> </div> </div> </div> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_sponsors"> <div class="sponsor_new sponsor-elem"> </div> <div class="other_sponser_sec"> <div class="container-fluid"> <div class="col-md-12" style=""> <h3>Exhibitors</h3> <ul style="float: none; text-align: center;"> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl06_rptSponsors_ctl01_imgSponsor" class="sponsor-image" src="/_media/partners/5589.png?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl01_lblName" class="hidden sponsor-name">Aptamer Group</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl01_lblType" class="hidden sponsor-type">Exhibitors</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl01_lblLink" class="hidden sponsor-link">http://www.aptamergroup.com</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl01_lblProfile" class="hidden sponsor-profile"><p>Aptamer Group develops custom affinity ligands for the life science industry through its proprietary Optimer® platform. Optimer binders are oligonucleotide-based affinity ligands that offer novel therapeutic solutions, from targeted delivery of diverse payloads to direct therapeutic moieties. They also support the drug pipeline with analytical and QC reagents. <p/> <p>Offering tuneable half-life, low immunogenicity, and the ability to hit new therapeutic targets, Optimer binders can enable new therapeutic breakthroughs to deliver science unlimited. <p/> </span> </div> </li> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl06_rptSponsors_ctl02_imgSponsor" class="sponsor-image" src="/_media/partners/5591.jpg?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl02_lblName" class="hidden sponsor-name">Asymchem</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl02_lblType" class="hidden sponsor-type">Exhibitors</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl02_lblLink" class="hidden sponsor-link">http://www.asymchem.com</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl02_lblProfile" class="hidden sponsor-profile"><p>At Asymchem we are proud of the strides that we have made since our founding in 1998, providing one-stop services the world's top pharmaceutical companies. Driving our success is our commitment to continual optimization and investing in the future.<p> <p>Our solutions range from development stage to commercial stage, including R&D and cGMP production of advanced intermediates, APls, drug product, biologics, ADCs, payload-inkers, peptides, oligonucleotides, as well as quality control, non-clinical/clinical research services and regulatory affairs. Through strategic partnerships and calculated business growth, we have built an integrated service ecosystem, with the know how to help our clients get things done<p></span> </div> </li> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl06_rptSponsors_ctl03_imgSponsor" class="sponsor-image" src="/_media/partners/5352.png?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl03_lblName" class="hidden sponsor-name">ChemGenes</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl03_lblType" class="hidden sponsor-type">Exhibitors</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl03_lblLink" class="hidden sponsor-link">https://www.chemgenes.com/</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl03_lblProfile" class="hidden sponsor-profile"><p>ChemGenes, an ISO 9001 certified company established in 1981, is the industry leader in manufacturing oligonucleotide synthesis reagents and has consistently provided the highest quality phosphoramidites and solid supports in the market. Our facility, just outside of Boston/Cambridge Massachusetts USA, is setup for bulk manufacturing of therapeutic grade phosphoramidite and solid support DNA/RNA synthesis products for GMP grade oligonucleotide manufacturing. ChemGenes carries the widest variety of modified phosphoramidites and supports currently used in oligonucleotide synthesis including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based Probes and other areas of Nucleic Acid research. In addition, ChemGenes is expanding its custom oligonucleotide synthesis department specializing in the manufacture of ASOs, siRNA, gRNA, gapmers, aptamers, DNA based probes, and superior quality beads for Single Cell mRNA sequencing applications using Drop-Seq, Slide-seq, and Seq-Well methods. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.<p> </span> </div> </li> </ul> </div> </div> <div class="clearfix"></div> <div class="buttons buttons_ed" style="margin-bottom: 40px;"> <a id="ctl00_MainContent_ctl06_rptSponsors_ctl04_lnkPopup" class="button-white open-popup-link" href="#pop-exhibitors">view all Exhibitors</a> <a href="#pop-sponsor" class="button-white open-popup-link">Sponsor the conference</a> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_partners"> <div class="sponsor_new sponsor-elem"> </div> <div class="sponsor_new sponsor-elem"> </div> <div class="other_sponser_sec"> <div class="container-fluid"> <div class="col-md-12" style=""> <h3>Supporters</h3> <ul style="float: none; text-align: center;"> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl09_rptSponsors_ctl01_imgSponsor" class="sponsor-image" src="/_media/partners/2391.jpg?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl01_lblName" class="hidden sponsor-name">ASD MEDIA</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl01_lblType" class="hidden sponsor-type">Supporters</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl01_lblLink" class="hidden sponsor-link">http://www.asd-network.com</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl01_lblProfile" class="hidden sponsor-profile">Professionals in the Aerospace & Defence market use the ASD Media internet platforms to: <ul> <li>Be informed on the latest market developments; www.asd-network.com</li> <li>Find the latest business news; www.asd-network.com</li> <li>Find the upcoming events; www.asd-network.com</li> <li>Find companies and organizations; www.asdsource.com</li> <li>Distribute news globally. www.asdwire.com</li> </ul> The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website. <br><br> For more detailed information please contact with: ASD MEDIA<br> Stefan.koopman@asdmedia.nl</span> </div> </li> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl09_rptSponsors_ctl02_imgSponsor" class="sponsor-image" src="/_media/partners/2403.jpg?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl02_lblName" class="hidden sponsor-name">Drug Development Technology</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl02_lblType" class="hidden sponsor-type">Supporters</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl02_lblLink" class="hidden sponsor-link">http://www.drugdevelopment-technology.com</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl02_lblProfile" class="hidden sponsor-profile">Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments. </span> </div> </li> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl09_rptSponsors_ctl03_imgSponsor" class="sponsor-image" src="/_media/partners/4371.jpg?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl03_lblName" class="hidden sponsor-name">Gene Therapy Net</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl03_lblType" class="hidden sponsor-type">Supporters</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl03_lblLink" class="hidden sponsor-link">http://www.genetherapynet.com</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl03_lblProfile" class="hidden sponsor-profile">Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines</span> </div> </li> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl09_rptSponsors_ctl04_imgSponsor" class="sponsor-image" src="/_media/partners/4110.png?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl04_lblName" class="hidden sponsor-name">Pharma Journalist </span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl04_lblType" class="hidden sponsor-type">Supporters</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl04_lblLink" class="hidden sponsor-link">http://www.pharmajournalist.com</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl04_lblProfile" class="hidden sponsor-profile">Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.</span> </div> </li> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl09_rptSponsors_ctl05_imgSponsor" class="sponsor-image" src="/_media/partners/2411.jpg?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl05_lblName" class="hidden sponsor-name">pharmaphorum</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl05_lblType" class="hidden sponsor-type">Supporters</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl05_lblLink" class="hidden sponsor-link">http://www.pharmaphorum.com</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl05_lblProfile" class="hidden sponsor-profile">pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com</span> </div> </li> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl09_rptSponsors_ctl06_imgSponsor" class="sponsor-image" src="/_media/partners/4284.jpg?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl06_lblName" class="hidden sponsor-name">The Medicine Maker</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl06_lblType" class="hidden sponsor-type">Supporters</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl06_lblLink" class="hidden sponsor-link">https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo</span> <span id="ctl00_MainContent_ctl09_rptSponsors_ctl06_lblProfile" class="hidden sponsor-profile"> The Medicine Maker is a print and digital publication as well as a weekly newsletter. At The Medicine Maker, we bring people into the limelight, showcasing the industry’s success stories and examining its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward. Register for your FREE print or digital magazine or subscribe to our newsletter here! https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo </span> </div> </li> </ul> </div> </div> <div class="clearfix"></div> <div class="buttons buttons_ed" style="margin-bottom: 40px;"> <a id="ctl00_MainContent_ctl09_rptSponsors_ctl07_lnkPopup" class="button-white open-popup-link" href="#pop-supporters">view all Supporters</a> <a href="#pop-sponsor" class="button-white open-popup-link">Sponsor the conference</a> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_associatedevents"> <div class="associate_event_sec"> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_venue"> <div class="venue_sec"> <h2 class="font_weght">VENUE</h2> <h2 class="font_weght2">Hilton London Kensington</h2> <p>179-199 Holland Park Avenue, London, United Kingdom</p> <div class="row"> <div class="col-sm-6"> <div class="venue_left"> <a href="#"><img src="/documentPortal/venueImages/319.jpg" alt="" /></a> </div> </div> <div class="col-sm-6"> <div class="venue_map"> <iframe src="https://www.google.com/maps/d/u/0/embed?mid=zDxkJou5X4vI.k2pc1IMkZJhg"></iframe> </div> </div> </div> <div class="row"> <div class="col-sm-12"> <div class="venue_details"> <p><p>At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.</p> <div style="margin: 0cm"> <div style="margin: 0cm"> </div> <div style="margin: 0cm">Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”</div> </div></p> <div style="text-align:left"> <strong>A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing SMi Group Trading As SAE Media Group. SMi Group Trading As SAE Media Group books all hotel rooms directly. If you are approached by a third-party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third-party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.</strong> </div> <a href="/documentPortal/hotelBookingForms/6017.pdf?v=1">HOTEL BOOKING FORM</a> </div> </div> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_downloads"> <div id="downloads"> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl14_rptDownloads_ctl00_hypDownload1" href="https://smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery?o=login&dpb=1&dl=cc&p1=6017&p2=5312"><img id="ctl00_MainContent_ctl14_rptDownloads_ctl00_imgDownload" src="/documentportal/ComplementaryContent/5312.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Speaker Interview - Dan Elbaum</h4> <a id="ctl00_MainContent_ctl14_rptDownloads_ctl00_hypDownload2" href="https://smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery?o=login&dpb=1&dl=cc&p1=6017&p2=5312">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl14_rptDownloads_ctl01_hypDownload1" href="https://smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery?o=login&dpb=1&dl=cc&p1=6017&p2=5313"><img id="ctl00_MainContent_ctl14_rptDownloads_ctl01_imgDownload" src="/documentportal/ComplementaryContent/5313.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Past Attendee List</h4> <a id="ctl00_MainContent_ctl14_rptDownloads_ctl01_hypDownload2" href="https://smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery?o=login&dpb=1&dl=cc&p1=6017&p2=5313">Download</a> </div> </div> </div>  </div> </div> </div> </div> </div> </div> </div> <div> <div class="container"> <div class="row"> <div class="col-sm-12"> <div id="ctl00_MainContent_ucEditorsCornerScroller_divEditorsCornerSlider" class="container-fluid strip"> <div class="container"> <h2>Editor’s Corner</h2> <div id="editorscorner-slider" class="slider hidden"> <div> <a id="ctl00_MainContent_ucEditorsCornerScroller_rptDownloads_ctl00_hypDownload1" href="/documentportal/ComplementaryContent/5229.pdf" target="_blank"><img id="ctl00_MainContent_ucEditorsCornerScroller_rptDownloads_ctl00_imgDownload" src="/documentportal/ComplementaryContent/5229.png?width=320&height=320&canvas=white" /></a> <a id="ctl00_MainContent_ucEditorsCornerScroller_rptDownloads_ctl00_hypDownload2" href="/documentportal/ComplementaryContent/5229.pdf" target="_blank"><h3>News - GSK to boost oligonucleotide development with latest acquisition</h3></a> </div> </div> </div> </div> </div> </div> </div> </div> <div id="pop-exhibitors" class="white-popup mfp-hide"> <h3 style="padding-left: 0"> Exhibitors</h3> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="http://www.aptamergroup.com" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/5589.png" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> Aptamer Group</h3> <div class="subtitle"> Exhibitors</div> <a href="http://www.aptamergroup.com" target="_blank" class="link" align="right"> http://www.aptamergroup.com</a> <br /> <br /> <div class="textbody"> <p>Aptamer Group develops custom affinity ligands for the life science industry through its proprietary Optimer® platform. Optimer binders are oligonucleotide-based affinity ligands that offer novel therapeutic solutions, from targeted delivery of diverse payloads to direct therapeutic moieties. They also support the drug pipeline with analytical and QC reagents. <p/> <p>Offering tuneable half-life, low immunogenicity, and the ability to hit new therapeutic targets, Optimer binders can enable new therapeutic breakthroughs to deliver science unlimited. <p/> </div> <br /> </div> </div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="http://www.asymchem.com" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/5591.jpg" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> Asymchem</h3> <div class="subtitle"> Exhibitors</div> <a href="http://www.asymchem.com" target="_blank" class="link" align="right"> http://www.asymchem.com</a> <br /> <br /> <div class="textbody"> <p>At Asymchem we are proud of the strides that we have made since our founding in 1998, providing one-stop services the world's top pharmaceutical companies. Driving our success is our commitment to continual optimization and investing in the future.<p> <p>Our solutions range from development stage to commercial stage, including R&D and cGMP production of advanced intermediates, APls, drug product, biologics, ADCs, payload-inkers, peptides, oligonucleotides, as well as quality control, non-clinical/clinical research services and regulatory affairs. Through strategic partnerships and calculated business growth, we have built an integrated service ecosystem, with the know how to help our clients get things done<p> </div> <br /> </div> </div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="https://www.chemgenes.com/" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/5352.png" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> ChemGenes</h3> <div class="subtitle"> Exhibitors</div> <a href="https://www.chemgenes.com/" target="_blank" class="link" align="right"> https://www.chemgenes.com/</a> <br /> <br /> <div class="textbody"> <p>ChemGenes, an ISO 9001 certified company established in 1981, is the industry leader in manufacturing oligonucleotide synthesis reagents and has consistently provided the highest quality phosphoramidites and solid supports in the market. Our facility, just outside of Boston/Cambridge Massachusetts USA, is setup for bulk manufacturing of therapeutic grade phosphoramidite and solid support DNA/RNA synthesis products for GMP grade oligonucleotide manufacturing. ChemGenes carries the widest variety of modified phosphoramidites and supports currently used in oligonucleotide synthesis including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based Probes and other areas of Nucleic Acid research. In addition, ChemGenes is expanding its custom oligonucleotide synthesis department specializing in the manufacture of ASOs, siRNA, gRNA, gapmers, aptamers, DNA based probes, and superior quality beads for Single Cell mRNA sequencing applications using Drop-Seq, Slide-seq, and Seq-Well methods. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.<p> </div> <br /> </div> </div> </div> <div id="pop-supporters" class="white-popup mfp-hide"> <h3 style="padding-left: 0"> Media Partners</h3> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="http://www.pharmaphorum.com" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/2411.jpg" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> pharmaphorum</h3> <div class="subtitle"> Supporters</div> <a href="http://www.pharmaphorum.com" target="_blank" class="link" align="right"> http://www.pharmaphorum.com</a> <br /> <br /> <div class="textbody"> pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com </div> <br /> </div> </div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="http://www.drugdevelopment-technology.com" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/2403.jpg" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> Drug Development Technology</h3> <div class="subtitle"> Supporters</div> <a href="http://www.drugdevelopment-technology.com" target="_blank" class="link" align="right"> http://www.drugdevelopment-technology.com</a> <br /> <br /> <div class="textbody"> Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments. </div> <br /> </div> </div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="http://www.pharmajournalist.com" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/4110.png" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> Pharma Journalist </h3> <div class="subtitle"> Supporters</div> <a href="http://www.pharmajournalist.com" target="_blank" class="link" align="right"> http://www.pharmajournalist.com</a> <br /> <br /> <div class="textbody"> Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers. </div> <br /> </div> </div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="http://www.asd-network.com" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/2391.jpg" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> ASD MEDIA</h3> <div class="subtitle"> Supporters</div> <a href="http://www.asd-network.com" target="_blank" class="link" align="right"> http://www.asd-network.com</a> <br /> <br /> <div class="textbody"> Professionals in the Aerospace & Defence market use the ASD Media internet platforms to: <ul> <li>Be informed on the latest market developments; www.asd-network.com</li> <li>Find the latest business news; www.asd-network.com</li> <li>Find the upcoming events; www.asd-network.com</li> <li>Find companies and organizations; www.asdsource.com</li> <li>Distribute news globally. www.asdwire.com</li> </ul> The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website. <br><br> For more detailed information please contact with: ASD MEDIA<br> Stefan.koopman@asdmedia.nl </div> <br /> </div> </div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="http://www.genetherapynet.com" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/4371.jpg" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> Gene Therapy Net</h3> <div class="subtitle"> Supporters</div> <a href="http://www.genetherapynet.com" target="_blank" class="link" align="right"> http://www.genetherapynet.com</a> <br /> <br /> <div class="textbody"> Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines </div> <br /> </div> </div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/4284.jpg" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> The Medicine Maker</h3> <div class="subtitle"> Supporters</div> <a href="https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo" target="_blank" class="link" align="right"> https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo</a> <br /> <br /> <div class="textbody"> The Medicine Maker is a print and digital publication as well as a weekly newsletter. At The Medicine Maker, we bring people into the limelight, showcasing the industry’s success stories and examining its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward. Register for your FREE print or digital magazine or subscribe to our newsletter here! https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo </div> <br /> </div> </div> </div> <div id="pop-ical" class="ical-popup mfp-hide"> <h3 style="padding-left: 0px; margin: 0px"> SAVE TO</h3> <br /> <img src="/_images/newsite/cal-1.jpg" alt="Outlook Calendar" />  <a href="/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery/event.ics" style="color: #000">OUTLOOK CALENDAR</a><br /> <img src="/_images/newsite/cal-2.jpg" alt="Google Calendar" />  <a href="http://www.google.com/calendar/event?action=TEMPLATE&text=Oligonucleotide+Therapeutics+and+Delivery&dates=20240909T070000Z/20240910T155000Z&details=SAE+Media+Group%27s+Oligonucleotide+Therapeutics+and+Delivery+conference+9th+-+10th+September+2023&location=Hilton+London+Kensington%2c+London&sprop=website:www.smi-online.co.uk" style="color: #000">GOOGLE CALENDAR</a><br /> <img src="/_images/newsite/cal-3.jpg" alt="ICal Calendar" />  <a href="/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery/event.ics" style="color: #000">ICAL CALENDAR</a><br /> <img src="/_images/newsite/cal-4.jpg" alt="Yahoo! Calendar" />  <a href="http://calendar.yahoo.com/?v=60&TYPE=18&TITLE=Oligonucleotide+Therapeutics+and+Delivery&ST=20240909T070000Z&ET=20240910T155000Z&in_loc=Hilton+London+Kensington%2c+London&DESC=SAE+Media+Group%27s+Oligonucleotide+Therapeutics+and+Delivery+conference+9th+-+10th+September+2023" style="color: #000">YAHOO! CALENDAR</a><br /> </div> <div id="pop-venue" class="white-popup mfp-hide"> <h3 style="padding-left: 0px; margin: 0px"> Hilton London Kensington</h3> 179-199 Holland Park Avenue<br/> London W11 4UL<br/> United Kingdom<br/> <br /> <div class="clearfix"> <div class="s-left-side" style="width: 50%; display: table-cell; vertical-align: top; float: left;"> <img src="/documentPortal/venueImages/319.jpg?width=350" alt="Hilton London Kensington" class="img-responsive" /> </div> <div class="s-right-side" style="width: 50%; display: table-cell; float: left; text-align: right"> <iframe class="iframe-map" style="height: 350px; width: 100%; padding-left: 10px; border: 0" src="https://www.google.com/maps/d/u/0/embed?mid=zDxkJou5X4vI.k2pc1IMkZJhg" frameborder="0"></iframe> </div> </div> <br /> <p>At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.</p> <div style="margin: 0cm"> <div style="margin: 0cm"> </div> <div style="margin: 0cm">Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”</div> </div> <div style="margin-top:20px;"> <a href="/documentPortal/hotelBookingForms/6017.pdf" class="log_btn" target="_blank">HOTEL BOOKING FORM</a> </div> </div> <div id="pop-speaker-single" class="white-popup mfp-hide"> <br /> <div class="clearfix"> <div class="s-left-side" style="width: 75%; display: table-cell; vertical-align: top; float: left;"> <h3 class="title" style="padding-left: 0px; margin: 0px"> Title</h3> <span class="subtitle">SubTitle</span> </div> <div class="s-right-side" style="width: 25%; display: table-cell; float: left;"> <img src="" alt="speaker image" class="img-responsive popup-image" align="right" /> </div> </div> <br /> <div class="textbody"> Content </div> </div> <div id="pop-media-single" class="white-popup mfp-hide"> <br /> <div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 75%; display: table-cell; vertical-align: top; float: left;"> <h3 class="title" style="padding-left: 0; margin: 0"> </h3> <div class="subtitle"> </div> <a href="" target="_blank" class="link"> </a> </div> <div class="s-right-side" style="width: 25%; display: table-cell; float: left;"> <a href="" target="_blank" class="imagelink"> <img src="" alt="sponsor image" class="img-responsive popup-image" align="right" /></a> </div> </div> <br /> <div class="textbody"> </div> </div> </div> <div id="pop-download" class="mfp-hide white-popup"> <h3 class="title" style="padding-left: 0px; margin: 0px">Title</h3><br /> <div class="desc">Description</div><br /> <a href="javascript:void(0)" class="link log_btn">Download</a> </div> <div id="pop-download-presentation" class="mfp-hide white-popup"> <h3 class="title" style="padding-left: 0px; margin: 0px">Title</h3><br /> <div class="desc">Description</div><br /> <a href="javascript:void(0)" class="link log_btn">Download</a> <a href="#pop-login" class="open-popup-link log_btn login_link">Login</a><br /> </div> <div id="pop-video" class="mfp-hide white-popup"> <h3 class="title" style="padding-left: 0px; margin: 0px">Title</h3><br /> <div class="desc">Description</div><br /> <div class="video"><iframe class="if" src="" width="640" height="564" frameborder="0" allow="autoplay; fullscreen" allowfullscreen></iframe></div><br /> <a href="javascript:void(0)" class="link log_btn">Download</a> <a href="#pop-login" class="open-popup-link log_btn login_link">Login</a><br /> </div> <div class="container-fluid darkgrey"> <footer class="container"> <div class="row"> <div class="col-xs-12 col-md-7" style="/*border:solid 1px white;*/"> <div class="contact-details" style="/*border:solid 1px white;*/"> <ul class="contact"> <li><a href="#pop-contact" class="open-popup-link">+44 (0)20 7827 6000</a></li> <li><a href="#pop-contact" class="open-popup-link">events@saemediagroup.com</a></li> </ul>  </div> <div class="participate" style="/*border:solid 1px white;*/"> <a href="#pop-speak" class="open-popup-link" style="color: #319dd8 !important">Speak</a> <a href="#pop-sponsor" class="open-popup-link" style="color: #319dd8 !important">Sponsor</a> <a href="#pop-attend" class="open-popup-link" style="color: #319dd8 !important">Attend</a> <a href="/about-us/help" style="color: #319dd8 !important">Help</a> <a href="/privacy-legals/privacy-policy" style="color: #319dd8 !important">Privacy Policy</a> <span style="color: #319dd8 !important"> <a href="#pop-register" class="open-popup-link" style="color: #319dd8 !important">Sign up</a>/<a href="#pop-login" class="open-popup-link" style="color: #319dd8 !important">Login</a> </span> </div> <div style="/*border:solid 1px white;*/"> <ul class="nav navbar-nav"> <li><a href="/Default.aspx">Home</a></li> <li> <a id="ctl00_footer_navbar_footer_list_rSector_ctl00_sLnk" href="/defence/">Defence & Security</a> </li> <li> <a id="ctl00_footer_navbar_footer_list_rSector_ctl01_sLnk" href="/utility/">Utilities</a> </li> <li> <a id="ctl00_footer_navbar_footer_list_rSector_ctl02_sLnk" class="sectorselected" href="/pharmaceuticals/">Pharmaceuticals</a> </li>  <li> <a href="https://www.saemediagroup.com" target="_blank">Digital & Print Media</a> </li> </ul> </div> </div> <div class="col-xs-12 col-md-5" style=""> <div class="row "> <div class="col-xs-12 col-sm-4"> <div class=""> <a href="/Default.aspx"><img alt="Home" src="/_images/newsite/logo.png" style="height:50px;"></a> </div> <div class=""> <span style="color: #fff; font-size: smaller;">Access insights, stay ahead and connected with industry leading conferences.</span> </div> </div> <div class="col-xs-12 col-sm-4"> <div class="" style=""> <div class="media"> <div class="media-left"> <a href="https://cuashub.com/en/" target="_blank"><img alt="C-UAS Hub" src="/_images/newsite/cuashub-logo-transparent.png" style="height:50px;"></a> </div> </div> </div> <div class=""> <span style="color: #fff; font-size: smaller;">Owned by SMG, C-UAS Hub is your central source for counter-UAS news and resources.</span> </div> </div> <div class="col-xs-12 col-sm-4 text-center" style=""> <div class="follow" style=""> <p>follow us</p> <a href="http://www.linkedin.com/company/407332" class="linkedin" target="_blank"></a> <a href="https://twitter.com/SAEMGPharma" class="twitter" target="_blank"></a> </div> </div> </div> </div> </div> </footer> <hr /> <p class="copyright"> copyright © 2025 SAE Media Group</p> </div> <style> .equal-height { display: flex; /* Make row a flex container */ align-items: stretch; /* Ensures columns have equal height */ } .centered-container { display: flex; align-items: center; /* Center content vertically */ justify-content: center; /* Center content horizontally */ height: 100%; /* Full height of the container */ } </style> <div id="cookie-use" class="cookie-use"> <div id="logo" class="cookie_img"> <a href="/"> <img alt="Home" src="/_images/newsite/logo.png" class="img-responsive" /></a> </div> <div class="cookie_content"> <h1> Cookie Policy</h1> <p> From May 2011 a new privacy law came into effect across the EU. The law requires that websites ask visitors for consent to use most web cookies. We use cookies to ensure you get the best experience on our website –Tick here to accept cookie use <input type="checkbox" id="cbAcceptCookieUse" /><br /> Details of our cookie use may be found <a href="/cookies">here</a>. </p> </div> </div> <script type="text/javascript"> //<![CDATA[ (function() {var fn = function() {$get("ctl00_ToolkitScriptManager1_HiddenField").value = '';Sys.Application.remove_init(fn);};Sys.Application.add_init(fn);})();//]]> </script> </form> <div id="pop-cpd" class="white-popup mfp-hide"> <img src="/_images/newsite/cpd-large.jpg"><br> <h3> WHAT IS CPD?</h3> <p> CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is: </p> <p> <i>‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’</i> </p> <p> CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities. </p> <p> Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld. </p> <p> CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading. </p> <h3> CPD AND PROFESSIONAL INSTITUTES</h3> <p> There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD. </p> <p> For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained. </p> <p> CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities. </p> <h3> TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)</h3> <p> Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based. </p> <p> <b>‘Input’</b> based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning. </p> <p> <b>‘Output’</b> based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning. </p> <p> The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently. </p> <p> As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements. </p> <h3> GLOBAL CPD</h3> <p> Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace. </p> <h3>CPD Certificates</h3> <p> We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email <a href="mailto:events@saemediagroup.com">events@saemediagroup.com</a> </p> </div> <div id="pop-news" class="white-popup mfp-hide"> <h3 class="news-evttitle" style="padding-left: 0px"> Event Title</h3> <h3 class="news-headline" style="padding-left: 0px"> Headline</h3> <div class="news-text"> Text </div> <a href="javascript:void(0)" class="news-evtlink log_btn" >Read More</a> </div> <div id="pop-speak" class="white-popup mfp-hide"> <div style="width: 100%"> <h3>I would like to speak at an event</h3> <div class="register_sec"> <form id="speak_form" action="" method="post"> <div class="ctrl-grp"> <label class="title"> Which conference are you interested in speaking at?</label> <select id="speak_conf" name="speak_conf" class="register-select conf_group"> <option value="">Select ...</option><option value="6073">AI in Drug Discovery</option><option value="6075">Future Soldier Technology</option><option value="6077">Military Robotics & Autonomous Systems</option><option value="6080">Counter UAS Technology Europe</option><option value="6103">Loitering Munitions USA</option><option value="6081">Smart Water Systems</option><option value="6084">Future Armoured Vehicles Situational Awareness</option><option value="6083">Military Space Situational Awareness </option><option value="6068">Pre-Filled Syringes and Injectable Drug Devices East Coast</option><option value="6093">Future Armoured Vehicles Central and Eastern Europe</option><option value="6094">Helicopter Technology Central and Eastern Europe</option><option value="6067">Pre-Filled Syringes and Injectable Drug Devices West Coast</option><option value="6097">Future Soldier Technology USA</option><option value="6099">MILSATCOM USA</option><option value="6092">Injectable Drug Delivery</option><option value="6106">Counter UAS Middle East & Africa</option><option value="6101">Military Robotics and Autonomous Systems USA</option><option value="6139">Wearable Injectors and Connected Devices USA </option><option value="6112">Unmanned Maritime Systems Technology USA</option><option value="6117">Future Armoured Vehicles Power Systems</option><option value="6114">The Space Logistics Conference</option><option value="6115">Defence Exports</option><option value="6108">Counter UAS Homeland Security Europe</option><option value="6118">UAV Technology</option><option value="6133">Defence Aviation Safety</option><option value="6105">Counter UAS Commercial Shipping</option><option value="6121">Airborne ISR</option><option value="6125">Global MilSatCom 2025</option><option value="6127">Transdermal and Microneedle Delivery</option><option value="6130">Air and Missile Defence Technology </option><option value="6132">Loitering Munitions</option><option value="6128">Future Armoured Vehicles Survivability</option><option value="6134">Energy From Waste</option><option value="6109">Counter UAS Technology USA</option><option value="6135">Military Airlift and Air-to-Air Refuelling</option><option value="6140">Pre-Filled Syringes and Injectable Drug Devices</option><option value="6143">Maritime Reconnaissance and Surveillance Technology</option><option value="6142">Mobile Deployable Communications</option><option value="6144">UAV Technology USA</option><option value="6145">Counter UAS Homeland Security USA</option> </select> </div> <div class="ctrl-grp"> <label class="title">Not listed above?</label> <input type="text" id="speak_notlisted" name="speak_notlisted" value="" class="form-control conf_group" spellcheck="false" /> </div> <div class="ctrl-grp"> <label class="title"> How can we help?</label> <textarea id="speak_help" name="speak_help" class="form-control"></textarea> </div> <div class="indent"> <div class="ctrl-grp"> <label>Organisation*</label> <input type="text" id="speak_org" name="speak_org" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Website</label> <input type="text" id="speak_website" name="speak_website" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Title</label>  <select id="speak_title" name="speak_title" class="form-control title_group" style="" spellcheck="false"> <option>Mr</option> <option>Mrs</option> <option>Miss</option> <option>Ms</option> <option>Dr</option> <option selected="selected">Select ...</option> <option>1st Lieutenant</option> <option>1st Sergeant</option> <option>2nd Lieutenant</option> <option>Admiral</option> <option>Admiral Sir</option> <option>Air Chief Marshall</option> <option>Air Commodore</option> <option>Air Marshal</option> <option>Air Vice Marshal</option> <option>Ambassador</option> <option>Archbishop</option> <option>Assistant Chief Constable</option> <option>Assistant Commissioner</option> <option>Assistant Director</option> <option>Assistant Professor</option> <option>Associate Professor</option> <option>Attorney</option> <option>Baron</option> <option>Baroness</option> <option>Bishop</option> <option>blank</option> <option>Brigadier</option> <option>Brigadier General</option> <option>Brigadier General (Ret’d)</option> <option>Brother</option> <option>Bsc</option> <option>Captain</option> <option>Chairman</option> <option>Chef de service administratif</option> <option>Chef D'escadron</option> <option>Chief</option> <option>Chief Constable</option> <option>Chief Inspector</option> <option>Chief Mast Sergeant</option> <option>Chief Petty Officer</option> <option>Chief Sergeant</option> <option>Chief Superintendent</option> <option>Colonel</option> <option>Colonel (Ret’d)</option> <option>Commandant</option> <option>Commander</option> <option>Commander Captain</option> <option>Commander General</option> <option>Commissaire Capitaine</option> <option>Commissaire Colonel</option> <option>Commissaire commandant</option> <option>Commissaire en chef</option> <option>Commissaire General</option> <option>Commissaire General de brigade</option> <option>Commissaire general de division</option> <option>Commissaire lieutenant</option> <option>Commissaire Lieutenant Colonel</option> <option>Commissaire principal</option> <option>Commissioner</option> <option>Commodore</option> <option>Commodore (Ret’d)</option> <option>Congressman</option> <option>Contre-Amiral</option> <option>Controleur des Armees</option> <option>Controleur general des armees</option> <option>Corporal</option> <option>Councillor</option> <option>Dame</option> <option>Datuk</option> <option>Deputy</option> <option>Deputy Assistant Commissioner</option> <option>Deputy Chief Constable</option> <option>Deputy Commissioner</option> <option>Deputy Director General</option> <option>Detective</option> <option>Detective Chief Inspector</option> <option>Detective Constable</option> <option>Detective Inspector</option> <option>Detective Sargeant</option> <option>Detective Superintendent</option> <option>Director</option> <option>Doctor</option> <option>Earl</option> <option>Esq</option> <option>Father</option> <option>Federal Agent</option> <option>Flight Lieutenant</option> <option>Flight Sergeant</option> <option>Frau</option> <option>Frau Dr</option> <option>General</option> <option>General (Ret'd)</option> <option>General Manager</option> <option>General Sir</option> <option>Governor</option> <option>Grand Duke</option> <option>Group Captain</option> <option>Herr</option> <option>Herr Dr</option> <option>His Excellency</option> <option>His Grace Most Rev</option> <option>His Highness</option> <option>His Honour</option> <option>His Majesty King</option> <option>His Royal Highness</option> <option>His Royal Highness Prince</option> <option>Honourable</option> <option>Honourable Dr</option> <option>Honourable Judge</option> <option>Honourable Mr Justice</option> <option>Ing</option> <option>Ingenieur des ETA</option> <option>Ingenieur d'etudes et de fabrications</option> <option>Ingenieur divissionaire des TPE</option> <option>Ingenieur en chef 1c des ETTM</option> <option>Ingenieur en chef de l'armement</option> <option>Ingenieur en chef de l'armentent</option> <option>Ingenieur en chef des ETA</option> <option>Ingenieur en chef des P et C</option> <option>Ingenieur general 2c de l'armemnt</option> <option>Ingenieur general de l'armement</option> <option>Ingenieur General hc de l'armement</option> <option>Ingenieur principal de l'armement</option> <option>Ingenieur principal des ETA</option> <option>Inspecteur principal des impots</option> <option>Inspector</option> <option>Inspector General</option> <option>Judge</option> <option>King</option> <option>Lady</option> <option>Lieutenant</option> <option>Lieutenant Commander</option> <option>Lieutenant Colonel</option> <option>Lieutenant Colonel (Ret'd)</option> <option>Lieutenant Commander</option> <option>Lieutenant General</option> <option>Lieutenant General Sir</option> <option>Lord</option> <option>Ma</option> <option>Madame</option> <option>Magistrat Lieutenant Colonel</option> <option>Major</option> <option>Major (Ret'd)</option> <option>Major Brigadier</option> <option>Major General</option> <option>Major General (ret'd)</option> <option>Major Sargeant</option> <option>Managing Director</option> <option>Master Sergeant</option> <option>Minister</option> <option>Monsieur</option> <option>Monsignor</option> <option>Most Reverend</option> <option>Most Reverend Archbishop</option> <option>Most Reverend Bishop</option> <option>Most Reverend Dr</option> <option>MP</option> <option>Mr.</option> <option>Ms.</option> <option>Msc</option> <option>myt</option> <option>Ph.D</option> <option>Police Constable</option> <option>Police Director</option> <option>President</option> <option>President & Chief Executive Officer</option> <option>Prince</option> <option>Prof</option> <option>Professor</option> <option>Professor Dame</option> <option>Professor Dr</option> <option>Rear Admiral</option> <option>Reverend</option> <option>Reverend Dr</option> <option>Reverend Professor</option> <option>Right Admiral</option> <option>Right Honourable</option> <option>Right Rev</option> <option>Rt Hon</option> <option>Rt Hon Dame</option> <option>Rt Hon Lord</option> <option>Rt Hon Lord Justice</option> <option>Rt Hon Sir</option> <option>Rt Honourable</option> <option>Rt Rev</option> <option>Rt Rev Dr</option> <option>Rt Rev Lord</option> <option>Rt Rev Mgr</option> <option>Rt Rev Monsignor</option> <option>Rt. Hon</option> <option>Senator</option> <option>Senior General</option> <option>Sergeant</option> <option>Sergeant Major</option> <option>Sheikh</option> <option>Sir</option> <option>Sister</option> <option>Sous-lieutenant</option> <option>Squadron Leader</option> <option>Squadron Leader (Ret'd)</option> <option>Staff Brigadier</option> <option>Staff Sergeant</option> <option>Sultan</option> <option>Superintendent</option> <option>Surgeon Commodore</option> <option>Surgeon Rear Admiral</option> <option>Surgeon Vice Admiral</option> <option>The Honourable</option> <option>The Honourable Dr</option> <option>The Honourable Lord</option> <option>The Honourable Miss</option> <option>The Honourable Mr</option> <option>The Honourable Mr Justice</option> <option>The Most Reverend</option> <option>The Right Honourable</option> <option>The Right Honourable Baroness</option> <option>The Right Honourable Lord</option> <option>The Right Honourable Sir</option> <option>The Right Reverend</option> <option>Very Reverend</option> <option>Very Reverend Dr</option> <option>Vice Admiral</option> <option>Vice Admiral d'escadre</option> <option>Vice Admiral Sir</option> <option>Vice Amiral d'escadre</option> <option>Vice Chairman</option> <option>Vice President</option> <option>Viscount</option> <option>Warrant Officer</option> <option>Wing Commander</option> <option>Other</option> </select> <div style="display:none;"> <input type="text" id="speak_title_other" name="speak_title_other" value="" class="form-control title_group" style="margin:10px 0 0 178px; background-color: #ccc;" spellcheck="false" disabled="disabled" /> </div> <script> $(document).ready(function () { $("#speak_title").change(function () { if ($("option:selected", this).text() == 'Other') { $('#speak_title_other').prop('disabled', false); $('#speak_title_other').css({ 'background-color': '#fff' }); $('#speak_title_other').parent().slideDown(); } else { $('#speak_title_other').val(''); $('#speak_title_other').prop('disabled', true); $('#speak_title_other').css({ 'background-color': '#ccc' }); $('#speak_title_other').parent().slideUp(); } }); }); </script> </div> <div class="ctrl-grp"> <label>First Name*</label> <input type="text" id="speak_firstname" name="speak_firstname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Surname*</label> <input type="text" id="speak_surname" name="speak_surname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Email*</label> <input type="text" id="speak_email" name="speak_email" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Phone*</label> <input type="text" id="speak_phone" name="speak_phone" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp ffh"> <label>Address*</label> <input type="text" id="speak_add" name="speak_add" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp"> <label class="title"> What is the topic you wish to speak about?</label> <textarea id="speak_topic" name="speak_topic" class="form-control"></textarea> </div> <div class="ctrl-grp checkbox-grp"> <div><input id="speak_returning" name="speak_returning" type="checkbox" /></div> <label for="speak_returning"> I'm a returning speaker from a previous event</label> </div> <div class="ctrl-grp"> <label class="title"> Where did you hear about SAE Media Group?</label> <input type="text" id="speak_hear" name="speak_hear" value="" class="form-control" /> </div> <input id="speak_submit" type="submit" value="SUBMIT DETAILS" class="log_btn" /> </form> </div> </div> </div> <div id="pop-attend-group" class="white-popup mfp-hide"></div> <div id="pop-attend" class="white-popup mfp-hide"> <div style="width: 100%"> <h3 id="popTitle">I would like to attend an event</h3> <h3 id="popGroupTitle">Group Booking</h3> <h4 id="popGroupSubTitle" style="padding-left:80px;">Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours</h4> <div class="register_sec"> <form id="attend_form" action="" method="post"> <div class="ctrl-grp" id="divAttendConf"> <label class="title">Which conference are you interested in attending?</label> <select id="attend_conf" name="attend_conf" class="register-select conf_group"> <option value="">Select ...</option><option value="6073">AI in Drug Discovery</option><option value="6075">Future Soldier Technology</option><option value="6077">Military Robotics & Autonomous Systems</option><option value="6080">Counter UAS Technology Europe</option><option value="6103">Loitering Munitions USA</option><option value="6081">Smart Water Systems</option><option value="6084">Future Armoured Vehicles Situational Awareness</option><option value="6083">Military Space Situational Awareness </option><option value="6068">Pre-Filled Syringes and Injectable Drug Devices East Coast</option><option value="6093">Future Armoured Vehicles Central and Eastern Europe</option><option value="6094">Helicopter Technology Central and Eastern Europe</option><option value="6067">Pre-Filled Syringes and Injectable Drug Devices West Coast</option><option value="6097">Future Soldier Technology USA</option><option value="6099">MILSATCOM USA</option><option value="6092">Injectable Drug Delivery</option><option value="6106">Counter UAS Middle East & Africa</option><option value="6101">Military Robotics and Autonomous Systems USA</option><option value="6139">Wearable Injectors and Connected Devices USA </option><option value="6112">Unmanned Maritime Systems Technology USA</option><option value="6117">Future Armoured Vehicles Power Systems</option><option value="6114">The Space Logistics Conference</option><option value="6115">Defence Exports</option><option value="6108">Counter UAS Homeland Security Europe</option><option value="6118">UAV Technology</option><option value="6133">Defence Aviation Safety</option><option value="6105">Counter UAS Commercial Shipping</option><option value="6121">Airborne ISR</option><option value="6125">Global MilSatCom 2025</option><option value="6127">Transdermal and Microneedle Delivery</option><option value="6130">Air and Missile Defence Technology </option><option value="6132">Loitering Munitions</option><option value="6128">Future Armoured Vehicles Survivability</option><option value="6134">Energy From Waste</option><option value="6109">Counter UAS Technology USA</option><option value="6135">Military Airlift and Air-to-Air Refuelling</option><option value="6140">Pre-Filled Syringes and Injectable Drug Devices</option><option value="6143">Maritime Reconnaissance and Surveillance Technology</option><option value="6142">Mobile Deployable Communications</option><option value="6144">UAV Technology USA</option><option value="6145">Counter UAS Homeland Security USA</option> </select> </div>   <div class="indent"> <div class="ctrl-grp" id="divGroupSize"> <label>Group size</label> <input type="text" id="attend_groupSize" name="attend_groupSize" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Organisation*</label> <input type="text" id="attend_org" name="attend_org" value="" class="form-control" spellcheck="false" /> </div>  <div class="ctrl-grp"> <label>Title</label>  <select id="attend_title" name="attend_title" class="form-control title_group" style="" spellcheck="false"> <option>Mr</option> <option>Mrs</option> <option>Miss</option> <option>Ms</option> <option>Dr</option> <option selected="selected">Select ...</option> <option>1st Lieutenant</option> <option>1st Sergeant</option> <option>2nd Lieutenant</option> <option>Admiral</option> <option>Admiral Sir</option> <option>Air Chief Marshall</option> <option>Air Commodore</option> <option>Air Marshal</option> <option>Air Vice Marshal</option> <option>Ambassador</option> <option>Archbishop</option> <option>Assistant Chief Constable</option> <option>Assistant Commissioner</option> <option>Assistant Director</option> <option>Assistant Professor</option> <option>Associate Professor</option> <option>Attorney</option> <option>Baron</option> <option>Baroness</option> <option>Bishop</option> <option>blank</option> <option>Brigadier</option> <option>Brigadier General</option> <option>Brigadier General (Ret’d)</option> <option>Brother</option> <option>Bsc</option> <option>Captain</option> <option>Chairman</option> <option>Chef de service administratif</option> <option>Chef D'escadron</option> <option>Chief</option> <option>Chief Constable</option> <option>Chief Inspector</option> <option>Chief Mast Sergeant</option> <option>Chief Petty Officer</option> <option>Chief Sergeant</option> <option>Chief Superintendent</option> <option>Colonel</option> <option>Colonel (Ret’d)</option> <option>Commandant</option> <option>Commander</option> <option>Commander Captain</option> <option>Commander General</option> <option>Commissaire Capitaine</option> <option>Commissaire Colonel</option> <option>Commissaire commandant</option> <option>Commissaire en chef</option> <option>Commissaire General</option> <option>Commissaire General de brigade</option> <option>Commissaire general de division</option> <option>Commissaire lieutenant</option> <option>Commissaire Lieutenant Colonel</option> <option>Commissaire principal</option> <option>Commissioner</option> <option>Commodore</option> <option>Commodore (Ret’d)</option> <option>Congressman</option> <option>Contre-Amiral</option> <option>Controleur des Armees</option> <option>Controleur general des armees</option> <option>Corporal</option> <option>Councillor</option> <option>Dame</option> <option>Datuk</option> <option>Deputy</option> <option>Deputy Assistant Commissioner</option> <option>Deputy Chief Constable</option> <option>Deputy Commissioner</option> <option>Deputy Director General</option> <option>Detective</option> <option>Detective Chief Inspector</option> <option>Detective Constable</option> <option>Detective Inspector</option> <option>Detective Sargeant</option> <option>Detective Superintendent</option> <option>Director</option> <option>Doctor</option> <option>Earl</option> <option>Esq</option> <option>Father</option> <option>Federal Agent</option> <option>Flight Lieutenant</option> <option>Flight Sergeant</option> <option>Frau</option> <option>Frau Dr</option> <option>General</option> <option>General (Ret'd)</option> <option>General Manager</option> <option>General Sir</option> <option>Governor</option> <option>Grand Duke</option> <option>Group Captain</option> <option>Herr</option> <option>Herr Dr</option> <option>His Excellency</option> <option>His Grace Most Rev</option> <option>His Highness</option> <option>His Honour</option> <option>His Majesty King</option> <option>His Royal Highness</option> <option>His Royal Highness Prince</option> <option>Honourable</option> <option>Honourable Dr</option> <option>Honourable Judge</option> <option>Honourable Mr Justice</option> <option>Ing</option> <option>Ingenieur des ETA</option> <option>Ingenieur d'etudes et de fabrications</option> <option>Ingenieur divissionaire des TPE</option> <option>Ingenieur en chef 1c des ETTM</option> <option>Ingenieur en chef de l'armement</option> <option>Ingenieur en chef de l'armentent</option> <option>Ingenieur en chef des ETA</option> <option>Ingenieur en chef des P et C</option> <option>Ingenieur general 2c de l'armemnt</option> <option>Ingenieur general de l'armement</option> <option>Ingenieur General hc de l'armement</option> <option>Ingenieur principal de l'armement</option> <option>Ingenieur principal des ETA</option> <option>Inspecteur principal des impots</option> <option>Inspector</option> <option>Inspector General</option> <option>Judge</option> <option>King</option> <option>Lady</option> <option>Lieutenant</option> <option>Lieutenant Commander</option> <option>Lieutenant Colonel</option> <option>Lieutenant Colonel (Ret'd)</option> <option>Lieutenant Commander</option> <option>Lieutenant General</option> <option>Lieutenant General Sir</option> <option>Lord</option> <option>Ma</option> <option>Madame</option> <option>Magistrat Lieutenant Colonel</option> <option>Major</option> <option>Major (Ret'd)</option> <option>Major Brigadier</option> <option>Major General</option> <option>Major General (ret'd)</option> <option>Major Sargeant</option> <option>Managing Director</option> <option>Master Sergeant</option> <option>Minister</option> <option>Monsieur</option> <option>Monsignor</option> <option>Most Reverend</option> <option>Most Reverend Archbishop</option> <option>Most Reverend Bishop</option> <option>Most Reverend Dr</option> <option>MP</option> <option>Mr.</option> <option>Ms.</option> <option>Msc</option> <option>myt</option> <option>Ph.D</option> <option>Police Constable</option> <option>Police Director</option> <option>President</option> <option>President & Chief Executive Officer</option> <option>Prince</option> <option>Prof</option> <option>Professor</option> <option>Professor Dame</option> <option>Professor Dr</option> <option>Rear Admiral</option> <option>Reverend</option> <option>Reverend Dr</option> <option>Reverend Professor</option> <option>Right Admiral</option> <option>Right Honourable</option> <option>Right Rev</option> <option>Rt Hon</option> <option>Rt Hon Dame</option> <option>Rt Hon Lord</option> <option>Rt Hon Lord Justice</option> <option>Rt Hon Sir</option> <option>Rt Honourable</option> <option>Rt Rev</option> <option>Rt Rev Dr</option> <option>Rt Rev Lord</option> <option>Rt Rev Mgr</option> <option>Rt Rev Monsignor</option> <option>Rt. Hon</option> <option>Senator</option> <option>Senior General</option> <option>Sergeant</option> <option>Sergeant Major</option> <option>Sheikh</option> <option>Sir</option> <option>Sister</option> <option>Sous-lieutenant</option> <option>Squadron Leader</option> <option>Squadron Leader (Ret'd)</option> <option>Staff Brigadier</option> <option>Staff Sergeant</option> <option>Sultan</option> <option>Superintendent</option> <option>Surgeon Commodore</option> <option>Surgeon Rear Admiral</option> <option>Surgeon Vice Admiral</option> <option>The Honourable</option> <option>The Honourable Dr</option> <option>The Honourable Lord</option> <option>The Honourable Miss</option> <option>The Honourable Mr</option> <option>The Honourable Mr Justice</option> <option>The Most Reverend</option> <option>The Right Honourable</option> <option>The Right Honourable Baroness</option> <option>The Right Honourable Lord</option> <option>The Right Honourable Sir</option> <option>The Right Reverend</option> <option>Very Reverend</option> <option>Very Reverend Dr</option> <option>Vice Admiral</option> <option>Vice Admiral d'escadre</option> <option>Vice Admiral Sir</option> <option>Vice Amiral d'escadre</option> <option>Vice Chairman</option> <option>Vice President</option> <option>Viscount</option> <option>Warrant Officer</option> <option>Wing Commander</option> <option>Other</option> </select> <div style="display:none;"> <input type="text" id="attend_title_other" name="attend_title_other" value="" class="form-control title_group" style="margin:10px 0 0 178px; background-color: #ccc;" spellcheck="false" disabled="disabled" /> </div> <script> $(document).ready(function () { $("#attend_title").change(function () { if ($("option:selected", this).text() == 'Other') { $('#attend_title_other').prop('disabled', false); $('#attend_title_other').css({ 'background-color': '#fff' }); $('#attend_title_other').parent().slideDown(); } else { $('#attend_title_other').val(''); $('#attend_title_other').prop('disabled', true); $('#attend_title_other').css({ 'background-color': '#ccc' }); $('#attend_title_other').parent().slideUp(); } }); }); </script> </div> <div class="ctrl-grp"> <label>First Name*</label> <input type="text" id="attend_firstname" name="attend_firstname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Surname*</label> <input type="text" id="attend_surname" name="attend_surname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Email*</label> <input type="text" id="attend_email" name="attend_email" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Phone*</label> <input type="text" id="attend_phone" name="attend_phone" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp ffh"> <label>Address*</label> <input type="text" id="attend_add" name="attend_add" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp checkbox-grp" id="divAttendReturning"> <div><input id="attend_returning" name="attend_returning" type="checkbox" /></div> <label for="attend_returning">I'm a returning attendee from a previous event</label> </div>  <input id="attend_submit" type="submit" value="SUBMIT DETAILS" class="log_btn" /> </form> </div> </div> </div> <div id="pop-sponsor" class="white-popup mfp-hide"> <div style="width: 100%"> <h3 id="hSponsorExhibit">I would like to sponsor/exhibit at an event</h3> <div class="register_sec"> <form id="sponsor_form" action="" method="post"> <div class="ctrl-grp" id="divWhichConf"> <label class="title">Which conference are you interested in sponsoring?</label> <select id="sponsor_conf" name="sponsor_conf" class="conf_group"> <option value="">Select ...</option><option value="6073">AI in Drug Discovery</option><option value="6075">Future Soldier Technology</option><option value="6077">Military Robotics & Autonomous Systems</option><option value="6080">Counter UAS Technology Europe</option><option value="6103">Loitering Munitions USA</option><option value="6081">Smart Water Systems</option><option value="6084">Future Armoured Vehicles Situational Awareness</option><option value="6083">Military Space Situational Awareness </option><option value="6068">Pre-Filled Syringes and Injectable Drug Devices East Coast</option><option value="6093">Future Armoured Vehicles Central and Eastern Europe</option><option value="6094">Helicopter Technology Central and Eastern Europe</option><option value="6067">Pre-Filled Syringes and Injectable Drug Devices West Coast</option><option value="6097">Future Soldier Technology USA</option><option value="6099">MILSATCOM USA</option><option value="6092">Injectable Drug Delivery</option><option value="6106">Counter UAS Middle East & Africa</option><option value="6101">Military Robotics and Autonomous Systems USA</option><option value="6139">Wearable Injectors and Connected Devices USA </option><option value="6112">Unmanned Maritime Systems Technology USA</option><option value="6117">Future Armoured Vehicles Power Systems</option><option value="6114">The Space Logistics Conference</option><option value="6115">Defence Exports</option><option value="6108">Counter UAS Homeland Security Europe</option><option value="6118">UAV Technology</option><option value="6133">Defence Aviation Safety</option><option value="6105">Counter UAS Commercial Shipping</option><option value="6121">Airborne ISR</option><option value="6125">Global MilSatCom 2025</option><option value="6127">Transdermal and Microneedle Delivery</option><option value="6130">Air and Missile Defence Technology </option><option value="6132">Loitering Munitions</option><option value="6128">Future Armoured Vehicles Survivability</option><option value="6134">Energy From Waste</option><option value="6109">Counter UAS Technology USA</option><option value="6135">Military Airlift and Air-to-Air Refuelling</option><option value="6140">Pre-Filled Syringes and Injectable Drug Devices</option><option value="6143">Maritime Reconnaissance and Surveillance Technology</option><option value="6142">Mobile Deployable Communications</option><option value="6144">UAV Technology USA</option><option value="6145">Counter UAS Homeland Security USA</option> </select> </div> <div class="ctrl-grp" id="divNotListed"> <label class="title">Not listed above?</label> <input id="sponsor_notlisted" name="sponsor_notlisted" type="text" value="" class="form-control conf_group" spellcheck="false" /> </div> <div class="ctrl-grp hidden"> <label class="title"> What type of sponsorship are you interested in?</label> <ul class="checkbox-list"> <li> <input id="sponsor_lead" name="sponsor_lead" type="checkbox" /> <label for="sponsor_lead">Lead Sponsor</label> </li> <li> <input id="sponsor_speaking" name="sponsor_speaking" type="checkbox" /> <label for="sponsor_speaking">Speaking</label> </li> <li> <input id="sponsor_exhibit" name="sponsor_exhibit" type="checkbox" /> <label for="sponsor_exhibit">Exhibit</label> </li> <li> <input id="sponsor_networking" name="sponsor_networking" type="checkbox" /> <label for="sponsor_networking">Networking Reception Sponsor</label> </li> <li> <input id="sponsor_coffee" name="sponsor_coffee" type="checkbox" /> <label for="sponsor_coffee">Coffee/Tea Break Sponsor</label> </li> <li> <input id="sponsor_lunch" name="sponsor_lunch" type="checkbox" /> <label for="sponsor_lunch">Lunch Sponsor</label> </li> <li> <input id="sponsor_branding" name="sponsor_branding" type="checkbox" /> <label for="sponsor_branding">Branding Package</label> </li> <li> <input id="sponsor_lanyards" name="sponsor_lanyards" type="checkbox" /> <label for="sponsor_lanyards">Lanyards Sponsor</label> </li> </ul> </div> <div class="indent"> <div class="ctrl-grp"> <label>Organisation*</label> <input type="text" id="sponsor_org" name="sponsor_org" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp hidden"> <label>Website</label> <input type="text" id="sponsor_website" name="sponsor_website" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Job Title*</label> <input type="text" id="sponsor_jobtitle" name="sponsor_jobtitle" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Title</label>  <select id="sponsorVar_title" name="sponsorVar_title" class="form-control title_group" style="" spellcheck="false"> <option>Mr</option> <option>Mrs</option> <option>Miss</option> <option>Ms</option> <option>Dr</option> <option selected="selected">Select ...</option> <option>1st Lieutenant</option> <option>1st Sergeant</option> <option>2nd Lieutenant</option> <option>Admiral</option> <option>Admiral Sir</option> <option>Air Chief Marshall</option> <option>Air Commodore</option> <option>Air Marshal</option> <option>Air Vice Marshal</option> <option>Ambassador</option> <option>Archbishop</option> <option>Assistant Chief Constable</option> <option>Assistant Commissioner</option> <option>Assistant Director</option> <option>Assistant Professor</option> <option>Associate Professor</option> <option>Attorney</option> <option>Baron</option> <option>Baroness</option> <option>Bishop</option> <option>blank</option> <option>Brigadier</option> <option>Brigadier General</option> <option>Brigadier General (Ret’d)</option> <option>Brother</option> <option>Bsc</option> <option>Captain</option> <option>Chairman</option> <option>Chef de service administratif</option> <option>Chef D'escadron</option> <option>Chief</option> <option>Chief Constable</option> <option>Chief Inspector</option> <option>Chief Mast Sergeant</option> <option>Chief Petty Officer</option> <option>Chief Sergeant</option> <option>Chief Superintendent</option> <option>Colonel</option> <option>Colonel (Ret’d)</option> <option>Commandant</option> <option>Commander</option> <option>Commander Captain</option> <option>Commander General</option> <option>Commissaire Capitaine</option> <option>Commissaire Colonel</option> <option>Commissaire commandant</option> <option>Commissaire en chef</option> <option>Commissaire General</option> <option>Commissaire General de brigade</option> <option>Commissaire general de division</option> <option>Commissaire lieutenant</option> <option>Commissaire Lieutenant Colonel</option> <option>Commissaire principal</option> <option>Commissioner</option> <option>Commodore</option> <option>Commodore (Ret’d)</option> <option>Congressman</option> <option>Contre-Amiral</option> <option>Controleur des Armees</option> <option>Controleur general des armees</option> <option>Corporal</option> <option>Councillor</option> <option>Dame</option> <option>Datuk</option> <option>Deputy</option> <option>Deputy Assistant Commissioner</option> <option>Deputy Chief Constable</option> <option>Deputy Commissioner</option> <option>Deputy Director General</option> <option>Detective</option> <option>Detective Chief Inspector</option> <option>Detective Constable</option> <option>Detective Inspector</option> <option>Detective Sargeant</option> <option>Detective Superintendent</option> <option>Director</option> <option>Doctor</option> <option>Earl</option> <option>Esq</option> <option>Father</option> <option>Federal Agent</option> <option>Flight Lieutenant</option> <option>Flight Sergeant</option> <option>Frau</option> <option>Frau Dr</option> <option>General</option> <option>General (Ret'd)</option> <option>General Manager</option> <option>General Sir</option> <option>Governor</option> <option>Grand Duke</option> <option>Group Captain</option> <option>Herr</option> <option>Herr Dr</option> <option>His Excellency</option> <option>His Grace Most Rev</option> <option>His Highness</option> <option>His Honour</option> <option>His Majesty King</option> <option>His Royal Highness</option> <option>His Royal Highness Prince</option> <option>Honourable</option> <option>Honourable Dr</option> <option>Honourable Judge</option> <option>Honourable Mr Justice</option> <option>Ing</option> <option>Ingenieur des ETA</option> <option>Ingenieur d'etudes et de fabrications</option> <option>Ingenieur divissionaire des TPE</option> <option>Ingenieur en chef 1c des ETTM</option> <option>Ingenieur en chef de l'armement</option> <option>Ingenieur en chef de l'armentent</option> <option>Ingenieur en chef des ETA</option> <option>Ingenieur en chef des P et C</option> <option>Ingenieur general 2c de l'armemnt</option> <option>Ingenieur general de l'armement</option> <option>Ingenieur General hc de l'armement</option> <option>Ingenieur principal de l'armement</option> <option>Ingenieur principal des ETA</option> <option>Inspecteur principal des impots</option> <option>Inspector</option> <option>Inspector General</option> <option>Judge</option> <option>King</option> <option>Lady</option> <option>Lieutenant</option> <option>Lieutenant Commander</option> <option>Lieutenant Colonel</option> <option>Lieutenant Colonel (Ret'd)</option> <option>Lieutenant Commander</option> <option>Lieutenant General</option> <option>Lieutenant General Sir</option> <option>Lord</option> <option>Ma</option> <option>Madame</option> <option>Magistrat Lieutenant Colonel</option> <option>Major</option> <option>Major (Ret'd)</option> <option>Major Brigadier</option> <option>Major General</option> <option>Major General (ret'd)</option> <option>Major Sargeant</option> <option>Managing Director</option> <option>Master Sergeant</option> <option>Minister</option> <option>Monsieur</option> <option>Monsignor</option> <option>Most Reverend</option> <option>Most Reverend Archbishop</option> <option>Most Reverend Bishop</option> <option>Most Reverend Dr</option> <option>MP</option> <option>Mr.</option> <option>Ms.</option> <option>Msc</option> <option>myt</option> <option>Ph.D</option> <option>Police Constable</option> <option>Police Director</option> <option>President</option> <option>President & Chief Executive Officer</option> <option>Prince</option> <option>Prof</option> <option>Professor</option> <option>Professor Dame</option> <option>Professor Dr</option> <option>Rear Admiral</option> <option>Reverend</option> <option>Reverend Dr</option> <option>Reverend Professor</option> <option>Right Admiral</option> <option>Right Honourable</option> <option>Right Rev</option> <option>Rt Hon</option> <option>Rt Hon Dame</option> <option>Rt Hon Lord</option> <option>Rt Hon Lord Justice</option> <option>Rt Hon Sir</option> <option>Rt Honourable</option> <option>Rt Rev</option> <option>Rt Rev Dr</option> <option>Rt Rev Lord</option> <option>Rt Rev Mgr</option> <option>Rt Rev Monsignor</option> <option>Rt. Hon</option> <option>Senator</option> <option>Senior General</option> <option>Sergeant</option> <option>Sergeant Major</option> <option>Sheikh</option> <option>Sir</option> <option>Sister</option> <option>Sous-lieutenant</option> <option>Squadron Leader</option> <option>Squadron Leader (Ret'd)</option> <option>Staff Brigadier</option> <option>Staff Sergeant</option> <option>Sultan</option> <option>Superintendent</option> <option>Surgeon Commodore</option> <option>Surgeon Rear Admiral</option> <option>Surgeon Vice Admiral</option> <option>The Honourable</option> <option>The Honourable Dr</option> <option>The Honourable Lord</option> <option>The Honourable Miss</option> <option>The Honourable Mr</option> <option>The Honourable Mr Justice</option> <option>The Most Reverend</option> <option>The Right Honourable</option> <option>The Right Honourable Baroness</option> <option>The Right Honourable Lord</option> <option>The Right Honourable Sir</option> <option>The Right Reverend</option> <option>Very Reverend</option> <option>Very Reverend Dr</option> <option>Vice Admiral</option> <option>Vice Admiral d'escadre</option> <option>Vice Admiral Sir</option> <option>Vice Amiral d'escadre</option> <option>Vice Chairman</option> <option>Vice President</option> <option>Viscount</option> <option>Warrant Officer</option> <option>Wing Commander</option> <option>Other</option> </select> <div style="display:none;"> <input type="text" id="sponsor_title_other" name="sponsor_title_other" value="" class="form-control title_group" style="margin:10px 0 0 178px; background-color: #ccc;" spellcheck="false" disabled="disabled" /> </div> <script> $(document).ready(function () { $("#sponsorVar_title").change(function () { if ($("option:selected", this).text() == 'Other') { $('#sponsor_title_other').prop('disabled', false); $('#sponsor_title_other').css({ 'background-color': '#fff' }); $('#sponsor_title_other').parent().slideDown(); } else { $('#sponsor_title_other').val(''); $('#sponsor_title_other').prop('disabled', true); $('#sponsor_title_other').css({ 'background-color': '#ccc' }); $('#sponsor_title_other').parent().slideUp(); } }); }); </script> </div> <div class="ctrl-grp"> <label>First Name*</label> <input type="text" id="sponsor_firstname" name="sponsor_firstname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Surname*</label> <input type="text" id="sponsor_surname" name="sponsor_surname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Email*</label> <input type="text" id="sponsor_email" name="sponsor_email" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Phone*</label> <input type="text" id="sponsor_phone" name="sponsor_phone" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp ffh"> <label>Address*</label> <input type="text" id="sponsor_add" name="sponsor_add" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp hidden"> <label class="title">What are your sponsorship goals?</label> <textarea id="sponsor_goals" name="sponsor_goals" class="form-control"></textarea> </div> <div class="ctrl-grp checkbox-grp hidden"> <div><input id="sponsor_returning" name="sponsor_returning" type="checkbox" value="true"></div> <label for="sponsor_returning">I'm a returning sponsor from a previous event</label> </div> <div class="ctrl-grp hidden"> <label class="title">Where did you hear about SAE Media Group?</label> <input id="sponsor_hear" name="sponsor_hear" type="text" value="" class="form-control" /> </div> <input id="sponsor_submit" type="submit" value="SUBMIT DETAILS" class="log_btn" /> </form> </div> </div> </div> <div id="pop-login" class="white-popup mfp-hide"> <div style="width: 100%"> <h3> SIGN UP OR LOGIN</h3> <div class="register_sec"> <div class="sign_linkd hidden"> <a href="javascript:void(0)">SIGN UP/LOG IN with linked in</a> </div> <form id="login_form" action="" method="post"> <input id="login_reload" type="hidden" value="" /> <div class="indent"> <div class="ctrl-grp"> <label> EMAIL*</label> <input id="login_email" name="login_email" type="text" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> PASSWORD*</label> <input id="login_password" name="login_password" type="password" value="" class="form-control" autocomplete="off" /> </div> </div> <div class="ctrl-grp checkbox-grp"> <input id="login_rememberme" name="login_rememberme" type="checkbox" /> <label for="login_rememberme"> Keep me signed in</label> </div> <div> <a href="#pop-register" id="sign_btn_link" class="open-popup-link sign_btn">Sign up</a> <input id="login_button" type="submit" value="Log In" class="log_btn" /> </div> <div style="margin-top: 20px;"> <a href="#pop-forgot" class="open-popup-link">Forgotten Password?</a> </div> </form> <div id="login_failed" style="display: none"> <p> Sorry, the login details you entered were not found. Please try again. Alternatively you may register a new account <a href="#pop-register" class="open-popup-link">here</a>. </p> <p> Accounts are locked after <span id="ctl00_popupLogin_maxAttempts">5</span> failed attempts.</p> </div> </div> </div> </div> <div id="pop-register" class="white-popup mfp-hide"> <div style="width: 100%"> <center> <img src="/_images/newsite/logo.png" style="text-align: center" /></center> <div class="register_sec"> <form id="register_form" action="" method="post"> <div class="indent"> <div class="ctrl-grp"> <label> EMAIL*</label> <input id="register_email" name="register_email" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> PASSWORD*</label> <input id="register_password" name="register_password" type="password" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> CONFIRM*</label> <input id="register_confirm" name="register_confirm" type="password" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label>TITLE*</label>  <select id="register_title" name="register_title" class="form-control title_group" style="" spellcheck="false"> <option>Mr</option> <option>Mrs</option> <option>Miss</option> <option>Ms</option> <option>Dr</option> <option selected="selected">Select ...</option> <option>1st Lieutenant</option> <option>1st Sergeant</option> <option>2nd Lieutenant</option> <option>Admiral</option> <option>Admiral Sir</option> <option>Air Chief Marshall</option> <option>Air Commodore</option> <option>Air Marshal</option> <option>Air Vice Marshal</option> <option>Ambassador</option> <option>Archbishop</option> <option>Assistant Chief Constable</option> <option>Assistant Commissioner</option> <option>Assistant Director</option> <option>Assistant Professor</option> <option>Associate Professor</option> <option>Attorney</option> <option>Baron</option> <option>Baroness</option> <option>Bishop</option> <option>blank</option> <option>Brigadier</option> <option>Brigadier General</option> <option>Brigadier General (Ret’d)</option> <option>Brother</option> <option>Bsc</option> <option>Captain</option> <option>Chairman</option> <option>Chef de service administratif</option> <option>Chef D'escadron</option> <option>Chief</option> <option>Chief Constable</option> <option>Chief Inspector</option> <option>Chief Mast Sergeant</option> <option>Chief Petty Officer</option> <option>Chief Sergeant</option> <option>Chief Superintendent</option> <option>Colonel</option> <option>Colonel (Ret’d)</option> <option>Commandant</option> <option>Commander</option> <option>Commander Captain</option> <option>Commander General</option> <option>Commissaire Capitaine</option> <option>Commissaire Colonel</option> <option>Commissaire commandant</option> <option>Commissaire en chef</option> <option>Commissaire General</option> <option>Commissaire General de brigade</option> <option>Commissaire general de division</option> <option>Commissaire lieutenant</option> <option>Commissaire Lieutenant Colonel</option> <option>Commissaire principal</option> <option>Commissioner</option> <option>Commodore</option> <option>Commodore (Ret’d)</option> <option>Congressman</option> <option>Contre-Amiral</option> <option>Controleur des Armees</option> <option>Controleur general des armees</option> <option>Corporal</option> <option>Councillor</option> <option>Dame</option> <option>Datuk</option> <option>Deputy</option> <option>Deputy Assistant Commissioner</option> <option>Deputy Chief Constable</option> <option>Deputy Commissioner</option> <option>Deputy Director General</option> <option>Detective</option> <option>Detective Chief Inspector</option> <option>Detective Constable</option> <option>Detective Inspector</option> <option>Detective Sargeant</option> <option>Detective Superintendent</option> <option>Director</option> <option>Doctor</option> <option>Earl</option> <option>Esq</option> <option>Father</option> <option>Federal Agent</option> <option>Flight Lieutenant</option> <option>Flight Sergeant</option> <option>Frau</option> <option>Frau Dr</option> <option>General</option> <option>General (Ret'd)</option> <option>General Manager</option> <option>General Sir</option> <option>Governor</option> <option>Grand Duke</option> <option>Group Captain</option> <option>Herr</option> <option>Herr Dr</option> <option>His Excellency</option> <option>His Grace Most Rev</option> <option>His Highness</option> <option>His Honour</option> <option>His Majesty King</option> <option>His Royal Highness</option> <option>His Royal Highness Prince</option> <option>Honourable</option> <option>Honourable Dr</option> <option>Honourable Judge</option> <option>Honourable Mr Justice</option> <option>Ing</option> <option>Ingenieur des ETA</option> <option>Ingenieur d'etudes et de fabrications</option> <option>Ingenieur divissionaire des TPE</option> <option>Ingenieur en chef 1c des ETTM</option> <option>Ingenieur en chef de l'armement</option> <option>Ingenieur en chef de l'armentent</option> <option>Ingenieur en chef des ETA</option> <option>Ingenieur en chef des P et C</option> <option>Ingenieur general 2c de l'armemnt</option> <option>Ingenieur general de l'armement</option> <option>Ingenieur General hc de l'armement</option> <option>Ingenieur principal de l'armement</option> <option>Ingenieur principal des ETA</option> <option>Inspecteur principal des impots</option> <option>Inspector</option> <option>Inspector General</option> <option>Judge</option> <option>King</option> <option>Lady</option> <option>Lieutenant</option> <option>Lieutenant Commander</option> <option>Lieutenant Colonel</option> <option>Lieutenant Colonel (Ret'd)</option> <option>Lieutenant Commander</option> <option>Lieutenant General</option> <option>Lieutenant General Sir</option> <option>Lord</option> <option>Ma</option> <option>Madame</option> <option>Magistrat Lieutenant Colonel</option> <option>Major</option> <option>Major (Ret'd)</option> <option>Major Brigadier</option> <option>Major General</option> <option>Major General (ret'd)</option> <option>Major Sargeant</option> <option>Managing Director</option> <option>Master Sergeant</option> <option>Minister</option> <option>Monsieur</option> <option>Monsignor</option> <option>Most Reverend</option> <option>Most Reverend Archbishop</option> <option>Most Reverend Bishop</option> <option>Most Reverend Dr</option> <option>MP</option> <option>Mr.</option> <option>Ms.</option> <option>Msc</option> <option>myt</option> <option>Ph.D</option> <option>Police Constable</option> <option>Police Director</option> <option>President</option> <option>President & Chief Executive Officer</option> <option>Prince</option> <option>Prof</option> <option>Professor</option> <option>Professor Dame</option> <option>Professor Dr</option> <option>Rear Admiral</option> <option>Reverend</option> <option>Reverend Dr</option> <option>Reverend Professor</option> <option>Right Admiral</option> <option>Right Honourable</option> <option>Right Rev</option> <option>Rt Hon</option> <option>Rt Hon Dame</option> <option>Rt Hon Lord</option> <option>Rt Hon Lord Justice</option> <option>Rt Hon Sir</option> <option>Rt Honourable</option> <option>Rt Rev</option> <option>Rt Rev Dr</option> <option>Rt Rev Lord</option> <option>Rt Rev Mgr</option> <option>Rt Rev Monsignor</option> <option>Rt. Hon</option> <option>Senator</option> <option>Senior General</option> <option>Sergeant</option> <option>Sergeant Major</option> <option>Sheikh</option> <option>Sir</option> <option>Sister</option> <option>Sous-lieutenant</option> <option>Squadron Leader</option> <option>Squadron Leader (Ret'd)</option> <option>Staff Brigadier</option> <option>Staff Sergeant</option> <option>Sultan</option> <option>Superintendent</option> <option>Surgeon Commodore</option> <option>Surgeon Rear Admiral</option> <option>Surgeon Vice Admiral</option> <option>The Honourable</option> <option>The Honourable Dr</option> <option>The Honourable Lord</option> <option>The Honourable Miss</option> <option>The Honourable Mr</option> <option>The Honourable Mr Justice</option> <option>The Most Reverend</option> <option>The Right Honourable</option> <option>The Right Honourable Baroness</option> <option>The Right Honourable Lord</option> <option>The Right Honourable Sir</option> <option>The Right Reverend</option> <option>Very Reverend</option> <option>Very Reverend Dr</option> <option>Vice Admiral</option> <option>Vice Admiral d'escadre</option> <option>Vice Admiral Sir</option> <option>Vice Amiral d'escadre</option> <option>Vice Chairman</option> <option>Vice President</option> <option>Viscount</option> <option>Warrant Officer</option> <option>Wing Commander</option> <option>Other</option> </select> <div style="display:none;"> <input type="text" id="register_title_other" name="register_title_other" value="" class="form-control title_group" style="margin:10px 0 0 178px; background-color: #ccc;" spellcheck="false" disabled="disabled" /> </div> <script> $(document).ready(function () { $("#register_title").change(function () { if ($("option:selected", this).text() == 'Other') { $('#register_title_other').prop('disabled', false); $('#register_title_other').css({ 'background-color': '#fff' }); $('#register_title_other').parent().slideDown(); } else { $('#register_title_other').val(''); $('#register_title_other').prop('disabled', true); $('#register_title_other').css({ 'background-color': '#ccc' }); $('#register_title_other').parent().slideUp(); } }); }); </script> </div> <div class="ctrl-grp"> <label> FIRST NAME*</label> <input id="register_firstname" name="register_firstname" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> SURNAME*</label> <input id="register_surname" name="register_surname" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> COUNTRY*</label> <select id="register_country" name="register_country" class="register-select"> <option value="">Select ...</option><option value="222">United Kingdom</option><option value="223">USA</option><option value="85">Germany</option><option value="78">France</option><option value="108">Italy</option><option value="102">India</option><option value="154">Netherlands</option><option value="205">Switzerland</option><option value="26">Belgium</option><option value="">------------------------------</option><option value="1">Afghanistan</option><option value="2">Albania</option><option value="3">Algeria</option><option value="4">American Samoa</option><option value="5">Andorra</option><option value="6">Angola</option><option value="7">Anguilla</option><option value="8">Antarctica-Casey</option><option value="9">Antarctica-Scott</option><option value="10">Antigua and Barbuda</option><option value="11">Argentina</option><option value="12">Armenia</option><option value="13">Aruba</option><option value="14">Ascension Islands</option><option value="15">Ashmore & Cartier Islands</option><option value="16">Atlantic East</option><option value="17">Atlantic West</option><option value="18">Australia</option><option value="19">Austria</option><option value="20">Azerbaijan</option><option value="21">Bahamas</option><option value="22">Bahrain</option><option value="23">Bangladesh</option><option value="24">Barbados</option><option value="25">Belarus</option><option value="27">Belize</option><option value="28">Benin</option><option value="29">Bermuda</option><option value="30">Bhutan</option><option value="31">Bolivia</option><option value="32">Bosnia and Herzegovina</option><option value="33">Botswana</option><option value="34">Brazil</option><option value="36">Brunei Darussalam</option><option value="37">Bulgaria</option><option value="38">Burkina Faso</option><option value="39">Burma</option><option value="40">Burundi</option><option value="41">Cambodia</option><option value="42">Cameroon</option><option value="43">Canada</option><option value="240">Canary Islands</option><option value="44">Cape Verde</option><option value="45">Cayman Islands</option><option value="46">Central African Republic</option><option value="47">Chad</option><option value="48">Chile</option><option value="49">China</option><option value="50">Christmas Island</option><option value="51">Clipperton Island</option><option value="52">Cocos (Keeling) Islands</option><option value="53">Colombia</option><option value="54">Comoros</option><option value="55">Congo</option><option value="56">Cook Islands</option><option value="57">Costa Rica</option><option value="58">Croatia</option><option value="59">Cuba</option><option value="60">Cyprus</option><option value="61">Czech Republic</option><option value="62">Denmark</option><option value="63">Djibouti</option><option value="64">Dominica</option><option value="65">Dominican Republic</option><option value="241">Easter Island</option><option value="67">Ecuador</option><option value="68">Egypt</option><option value="69">El Salvador</option><option value="70">Equatorial Guinea</option><option value="71">Eritrea</option><option value="72">Estonia</option><option value="73">Ethiopia</option><option value="254">Europe</option><option value="74">Falkland Islands</option><option value="75">Faroe Islands</option><option value="76">Fiji</option><option value="77">Finland</option><option value="79">French Guiana</option><option value="80">French Polynesia</option><option value="81">Gabon</option><option value="242">Galapagos Islands</option><option value="82">Gambia</option><option value="83">Gaza Strip</option><option value="84">Georgia</option><option value="86">Ghana</option><option value="87">Gibraltar</option><option value="88">Greece</option><option value="89">Greenland</option><option value="90">Grenada</option><option value="91">Guadeloupe</option><option value="92">Guam</option><option value="93">Guatemala</option><option value="94">Guinea</option><option value="95">Guinea-Bissau</option><option value="96">Guyana</option><option value="97">Haiti</option><option value="252">Hawaii</option><option value="98">Honduras</option><option value="99">Hong Kong</option><option value="100">Hungary</option><option value="101">Iceland</option><option value="103">Indonesia</option><option value="104">Iran, Islamic Republic of</option><option value="105">Iraq</option><option value="106">Ireland</option><option value="107">Israel</option><option value="110">Ivory Coast</option><option value="111">Jamaica</option><option value="112">Japan</option><option value="113">Jordan</option><option value="114">Kazakhstan</option><option value="115">Kenya</option><option value="116">Kiribati</option><option value="119">Kuwait</option><option value="120">Kyrgyzstan</option><option value="121">Laos</option><option value="122">Latvia</option><option value="123">Lebanon</option><option value="124">Lesotho</option><option value="125">Liberia</option><option value="126">Libya</option><option value="127">Liechtenstein</option><option value="128">Lithuania</option><option value="129">Luxembourg</option><option value="130">Macau</option><option value="131">Macedonia</option><option value="132">Madagascar</option><option value="133">Malawi</option><option value="134">Malaysia</option><option value="135">Maldives</option><option value="136">Mali</option><option value="137">Malta</option><option value="163">Marianas Islands</option><option value="138">Marshall Islands</option><option value="139">Martinique</option><option value="140">Mauritania</option><option value="141">Mauritius</option><option value="142">Mayotte Islands</option><option value="143">Mexico</option><option value="144">Micronesia</option><option value="145">Moldova</option><option value="146">Monaco</option><option value="147">Mongolia</option><option value="244">Montenegro</option><option value="148">Montserrat</option><option value="149">Morocco</option><option value="150">Mozambique</option><option value="245">Myanmar</option><option value="151">Namibia</option><option value="152">Nauru</option><option value="153">Nepal</option><option value="155">Netherlands Antilles</option><option value="156">New Caledonia</option><option value="157">New Zealand</option><option value="158">Nicaragua</option><option value="159">Niger</option><option value="160">Nigeria</option><option value="161">Niue</option><option value="255">None</option><option value="162">Norfolk Island</option><option value="117">North Korea</option><option value="164">Norway</option><option value="165">Oman</option><option value="166">Pakistan</option><option value="167">Palau</option><option value="251">Palestine</option><option value="168">Panama</option><option value="169">Papua New Guinea</option><option value="170">Paraguay</option><option value="171">Peru</option><option value="172">Philippines</option><option value="173">Poland</option><option value="174">Portugal</option><option value="175">Puerto Rico</option><option value="176">Qatar</option><option value="177">Réunion</option><option value="178">Romania</option><option value="179">Russia</option><option value="180">Rwanda</option><option value="181">Saint Helena</option><option value="182">Saint Kitts and Nevis</option><option value="183">Saint Lucia</option><option value="184">Saint Vincent/Grenadines</option><option value="185">Samoa</option><option value="186">San Marino</option><option value="187">Sao Tome</option><option value="188">Saudi Arabia</option><option value="253">Scotland</option><option value="189">Senegal</option><option value="246">Serbia</option><option value="190">Seychelles</option><option value="191">Sierra Leone</option><option value="192">Singapore</option><option value="193">Slovakia</option><option value="194">Slovenia</option><option value="195">Solomon Islands</option><option value="196">Somalia</option><option value="197">Somoa Western</option><option value="198">South Africa</option><option value="118">South Korea</option><option value="199">Spain</option><option value="200">Sri Lanka</option><option value="201">Sudan</option><option value="202">Suriname</option><option value="203">Swaziland</option><option value="204">Sweden</option><option value="206">Syria</option><option value="247">Tahiti</option><option value="207">Taiwan</option><option value="208">Tajikistan</option><option value="209">Tanzania</option><option value="248">Tatarstan</option><option value="256">TBC</option><option value="210">Thailand</option><option value="211">Togo</option><option value="212">Tonga</option><option value="213">Trinidad and Tobago</option><option value="214">Tunisia</option><option value="215">Turkey</option><option value="216">Turkmenistan</option><option value="217">Turks and Caicos Islands</option><option value="218">Tuvalu</option><option value="219">Uganda</option><option value="220">Ukraine</option><option value="221">United Arab Emirates</option><option value="224">Uruguay</option><option value="225">Uzbekistan</option><option value="249">Vanatu</option><option value="226">Vanuatu</option><option value="227">Vatican City (Holy See)</option><option value="228">Venezuela</option><option value="229">Vietnam</option><option value="35">Virgin Islands, British</option><option value="230">Virgin Islands, U.S.</option><option value="231">Wallis And Futuna</option><option value="232">West Bank</option><option value="250">West Indies</option><option value="233">Western Sahara</option><option value="234">Yemen</option><option value="235">Yugoslavia</option><option value="236">Zaire</option><option value="237">Zambia</option><option value="238">Zimbabwe</option> </select> </div> <div class="ctrl-grp"> <label> ORGANISATION*</label> <input id="register_org" name="register_org" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> JOB TITLE*</label> <input id="register_jobtitle" name="register_jobtitle" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> PHONE*</label> <input id="register_phone" name="register_phone" type="text" value="" class="form-control" /> </div> </div> <div class="ctrl-grp checkbox-grp"> <div><input id="register_subscribe" name="register_subscribe" type="checkbox" /></div> <label for="register_subscribe"> I would like to receive information about other SAE Media Group products and services</label> </div> <div class="ctrl-grp checkbox-grp"> <div> <input id="register_rememberme" name="register_rememberme" type="checkbox" /></div> <label for="register_rememberme"> Keep me logged in</label> </div> <div class="ctrl-grp checkbox-grp"> <div> <input id="register_terms" name="register_terms" type="checkbox" /></div> <label for="register_terms"> * I have read and understood the full Terms of Use (please click <a href="/privacy-legals/terms-of-use" target="_blank">here</a> to see full Terms of Use - please note these will open in a new window). These Terms and Conditions are governed by English law.</label> </div> <input id="register_signup" type="submit" value="Sign up" class="log_btn" /> </form> <label id="register_error" class="error" style="display: none"> </label> </div> </div> </div> <div id="pop-contact" class="white-popup mfp-hide"> <div style="col-md-6"> <h3> Contact SAE Media Group</h3> <div class="register_sec"> <span style="color: #08478c">UK Office</span><br /> Opening Hours: 9.00 - 17.30 (local time)<br /> SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom<br /> Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001<br /> Website: <a href="https://www.smgconferences.com/" style="color: #08478c">http://www.smgconferences.com</a> Email: <a href="mailto:events@saemediagroup.com" style="color: #08478c">events@saemediagroup.com</a><br /> Registered in England - SMi Group Ltd trading as SAE Media Group<br /> <br /> <form id="contact_form" action="" method="post"> <div class="ctrl-grp"> <label class="title"> Nature of your enquiry</label><br /> <select id="contact_enquirytype" name="contact_enquirytype" class="register-select conf_group" style="width: 88%;"> <option value="0">I have an enquiry that is not listed below</option><option value="1">I am an existing delegate on a Conference/Workshop</option><option value="2">I have a general Conference/Executive Briefing query</option><option value="3">I am interested in attending an SAE Media Group Conference as a delegate</option><option value="4">I am interested in attending an SAE Media Group Workshop/Executive Briefing as a delegate</option><option value="5">I am interested in attending an SAE Media Group Masterclass as a delegate</option><option value="6">I am interested in speaking at an SAE Media Group event</option><option value="7">I am interested in sponsoring/exhibiting at an SAE Media Group event</option><option value="8">I am interested in marketing opportunities with SAE Media Group</option><option value="9">I am interested in employment opportunities SAE Media Group</option><option value="10">I would like to suggest a Conference topic</option><option value="11">I would like to suggest a Workshop/Executive Briefing topic</option><option value="12">I would like to suggest a Masterclass topic</option><option value="13">I have a technical query regarding this web site</option><option value="15">SAE Media Group Event Communities Related</option><option value="17">Sponsor Webinars</option><option value="14">Other</option> </select> </div> <div class="indent"> <div class="ctrl-grp"> <label> Name*</label> <input type="text" id="contact_name" name="contact_name" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Job Title*</label> <input type="text" id="contact_jobtitle" name="contact_jobtitle" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Organisation*</label> <input type="text" id="contact_org" name="contact_org" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Phone*</label> <input type="text" id="contact_phone" name="contact_phone" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Email*</label> <input type="text" id="contact_email" name="contact_email" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp"> <label class="title"> Enquiry*</label> <textarea class="form-control" id="contact_enquiry" name="contact_enquiry"></textarea> </div> <input type="submit" value="SUBMIT DETAILS" class="log_btn" /> </form> </div> </div> </div> <div id="pop-sponsor-single" class="white-popup mfp-hide"> <br /> <div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 75%; display: table-cell; vertical-align: top; float: left;"> <h3 class="title" style="padding-left: 0; margin: 0"> </h3> <div class="subtitle"> </div> <a href="" target="_blank" class="link"> </a> </div> <div class="s-right-side" style="width: 25%; display: table-cell; float: left;"> <a href="" target="_blank" class="imagelink"> <img src="" alt="sponsor image" class="img-responsive popup-image" align="right" /></a> </div> </div> <br /> <div class="textbody"> </div> </div> </div> <div id="pop-forgot" class="white-popup mfp-hide"> <div style="width: 100%"> <h3> Forgotten Password</h3> <div class="register_sec"> <form id="forgot_form" action="" method="post"> <span>Please enter the email address you registered with. We will email you a new password.</span> <div class="indent"> <div class="ctrl-grp"> <label> EMAIL*</label> <input id="login_email" name="login_email" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <input id="forgot_button" type="submit" value="Reset Password" class="log_btn" /> </form> <div id="reset_successful" style="display:none;"> <div>You have been sent an email with your new password. When you have recieved this email please continue to logon. Thank you.</div> <a href="#pop-login" class="open-popup-link log_btn">Continue</a> </div> <div id="reset_failed" style="display:none;"> <div>Sorry, we could not reset your password. Have you entered the correct email address?</div> </div> </div> </div> </div> <div id="pop-GDPRConsent" class="white-popup mfp-hide"> <div style="width: 100%"> <h3>Thank you for visiting our event</h3> <div class="register_sec"> <form id="GDPRConsent_form" action="" method="post"> <input id="GDPRConsent_eventid" name="GDPRConsent_eventid" type="hidden" value="" /> <div class="ctrl-grp"> <h4>If you would like to receive further information about our events, please fill out the information below.</h4> </div> <div class="ctrl-grp"> <div style="float: left;margin-top:10px;"> <label>I am happy to receive information about SAE Media Group events by email:</label> </div> <div style="float: left;"> <input id="GDPRConsent_confirm" name="GDPRConsent_confirm" type="checkbox" value="" class="form-control" style="margin-left:20px;" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Your email address:</label> <input id="GDPRConsent_email" name="GDPRConsent_email" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Your name:</label> <input id="GDPRConsent_name" name="GDPRConsent_name" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Your phone number:</label> <input id="GDPRConsent_phone" name="GDPRConsent_phone" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div> <input id="GDPRConsent_button" type="submit" value="Submit" class="log_btn" /> </div> <div style="margin-top: 20px;"> By ticking above you are consenting to receive information by email from SAE Media Group.<br /> Full details of our privacy policy can be found here <a class="open-popup-link" href="https://www.smgconferences.com/privacy-legals/privacy-policy/">https://www.smgconferences.com/privacy-legals/privacy-policy/</a>.<br /> Should you wish to update your contact preferences at any time you can contact us at <a class="open-popup-link" href="mailto:data.privacy@smgconferences.com">data.privacy@smgconferences.com</a>.<br /> Should you wish to be removed from any future mailing lists please click on the following link <a class="open-popup-link" href="http://www.smgconferences.com/opt-out">http://www.smgconferences.com/opt-out</a> </div> </form> <div id="GDPRConsent_failed" style="display: none"> <p> Sorry, the login details you entered were not found. Please try again. Alternatively you may register a new account <a href="#pop-register" class="open-popup-link">here</a>. </p> </div> </div> </div> </div> <form></form> <div id="pop-DownloadBrochure" class="white-popup mfp-hide"> <div style="width: 100%"> <h3>Fill in your details to download the brochure</h3> <div class="register_sec"> <form id="DownloadBrochure_Form" action="" method="post"> <input id="DownloadBrochure_EventID" name="DownloadBrochure_EventID" type="hidden" value="" /> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">First Name</label> <input id="DownloadBrochure_FirstName" name="DownloadBrochure_FirstName" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Last Name</label> <input id="DownloadBrochure_LastName" name="DownloadBrochure_LastName" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Email Address*</label> <input id="DownloadBrochure_Email" name="DownloadBrochure_Email" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Company Name*</label> <input id="DownloadBrochure_CompanyName" name="DownloadBrochure_CompanyName" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Telephone Number*</label> <input id="DownloadBrochure_TelephoneNumber" name="DownloadBrochure_TelephoneNumber" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp"> <div style="float: left;"> <input id="DownloadBrochure_Confirm" name="DownloadBrochure_Confirm" type="checkbox" value="" class="form-control hidden" style="margin-left:20px;" checked /> </div> </div> <div> <input id="DownloadBrochure_Button" type="submit" value="Submit" class="log_btn" /> </div> <div style="margin-top:20px; font-weight:500;"> By submitting this form you agree to our <a href="/privacy-legals/privacy-policy/">privacy policy</a> and consent to receiving communications, you may opt out at any time. </div> <div class="hidden" style="margin-top: 20px;"> By ticking above you are consenting to receive information by email from SAE Media Group.<br /> Full details of our privacy policy can be found here <a class="open-popup-link" href="https://www.smgconferences.com/privacy-legals/privacy-policy/">https://www.smgconferences.com/privacy-legals/privacy-policy/</a>.<br /> Should you wish to update your contact preferences at any time you can contact us at <a class="open-popup-link" href="mailto:data@smgconferences.com">data@smgconferences.com</a>.<br /> Should you wish to be removed from any future mailing lists please click on the following link <a class="open-popup-link" href="http://www.smgconferences.com/opt-out">http://www.smgconferences.com/opt-out</a> </div> </form> </div> </div> </div> <div id="pop-KeepUpToDate" class="white-popup mfp-hide"> <div style="width: 100%"> <div id="KeepUpToDate_Sucess" style="display:none;"> <h3>Success! Your details have been submitted.</h3> <div class="register_sec">You will now receive the monthly loitering munitions newsletter.</div> </div> <form id="KeepUpToDate_Form" action="" method="post"> <h3>Join the loitering munitions community</h3> <div class="register_sec"> <div style="margin-top: 20px;"> Keep up to date with industry news, insights, and community updates <strong>FREE</strong> and direct to your inbox every month! </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">First Name</label> <input id="KeepUpToDate_FirstName" name="KeepUpToDate_FirstName" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Last Name</label> <input id="KeepUpToDate_LastName" name="KeepUpToDate_LastName" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Email Address*</label> <input id="KeepUpToDate_Email" name="KeepUpToDate_Email" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div style="margin-top: 20px;"> You can unsubscribe at any time. For full details see our <a class="open-popup-link" href="/privacy-legals/privacy-policy/">Privacy Policy</a> </div> <div> <input id="KeepUpToDate_Button" type="submit" value="Subscribe" class="log_btn"/> </div> </form> </div> </div> </div> <script type="text/javascript"> _linkedin_partner_id = "1595001"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); </script><script type="text/javascript"> (function(){var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);})(); </script> <noscript> <img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1595001&fmt=gif" /> </noscript> <script> (function(ss,ex){ window.ldfdr=window.ldfdr||function(){(ldfdr._q=ldfdr._q||[]).push([].slice.call(arguments));}; (function(d,s){ fs=d.getElementsByTagName(s)[0]; function ce(src){ var cs=d.createElement(s); cs.src=src; cs.async=1; fs.parentNode.insertBefore(cs,fs); }; ce('https://sc.lfeeder.com/lftracker_v1_'+ss+(ex?'_'+ex:'')+'.js'); })(document,'script'); })('p1e024BvLJX4GB6d'); </script> </body> </html>

CINXE.COM

Oligonucleotide Therapeutics and Delivery : Pharmaceuticals : UK